BC_Unique_MIP_Code,BC_Unique_MIP_Code_System,HC_DIN,BC PIN,MIP_Product_Name,MIP_SCT_Code,MIP_SCT_Formal_Name,Concat_Form,Concat_Route,Unit_of_Presentation_Code,Unit_Of_Presentation_Name,Descriptor,Number_of_AIS,Non-proprietary Therapeutic Product Name,Market_Authorization_Holder,DIA_SCT_Code,DIA_SCT_Formal_Name,DIA_Short_Name,DIA_Abbreviation,IA_SCT_Code,IA_SCT_Formal_Name,IA_Short_Name,IA_Abbreviation,WHO_ATC_Code,WHO_ATC_Name,Display_Name,Availability,MIP_Last_Status,Date,Monograph_URL,Health Canada -DPD-Link
33391000087109,SNOMED-CT,,,Abdala,33391000087109,Abdala COVID-19 recombinant spike protein vaccine (real medicinal product),,,,,,,,"Center for Genetic Engineering and Biotechnology (CIGB), The Havana",1162643001,Vaccine product containing only Severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN04,covid-19 protein subunit,COVID-19 Abdala,International,Added,2022-03-31,https://covid19.trackvaccines.org/vaccines/67/,
02544040,Health_Canada,02544040,,Abrysvo,55351000087104,ABRYSVO 120 micrograms per 0.5 milliliter powder for suspension Pfizer Canada ULC (real clinical drug),powder for solution AND kit,intramuscular,733020007,Syringe (unit of presentation),,2,rsv subgroup a stabilized prefusion f protein 60 mcg / 0.5 mL with rsv subgroup b stabilized prefusion f protein 60 mcg / 0.5 mL kit (powder for solution) for injection,Pfizer Canada Ulc,61771000087101,Vaccine product containing only Human orthopneumovirus messenger ribonucleic acid (medicinal product),Respiratory syncytial virus recombinant,RSV recomb,51311000087100,Vaccine product containing only Human orthopneumovirus antigen (medicinal product),RSV antigen,RSV mRNA,J07BX05,respiratory syncytial virus vaccine,RSV ABRYSVO Pfiz,Marketed,Added,2024-04-03,https://pdf.hres.ca/dpd_pm/00073900.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103244
02543699,Health_Canada,02543699,,Acam2000,56761000087108,ACAM2000 250000 to 1250000 plaque forming units per 2.5 microliter powder and diluent for solution for percutaneous scarification Emergent Product Development Gaithersburg Inc. (real clinical drug),powder for solution,percutaneous,733026001,Vial (unit of presentation),,1,,Emergent Product Development Gaithersburg Inc,1269346004,Vaccine product containing only live attenuated Vaccinia virus antigen (medicinal product),Vaccinia attenuated virus,VACV-LA,871727001,Vaccine product containing only Vaccinia virus antigen (medicinal product),Small pox,Sma,J07BX01,smallpox and monkeypox vaccines,Sma ACAM2000 EPDG,Restricted,Modified,2024-09-19,https://pdf.hres.ca/dpd_pm/00073682.PDF,
02238683,Health_Canada,02238683,,Actacel,23711000087101,ACTacel powder and diluent for solution for injection Sanofi Pasteur Limited (real clinical drug),liquid,intramuscular,733026001,Vial (unit of presentation),,8,diphtheria toxoid 15 LF / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 5 mcg / 0.5 mL + fimbriae (b. pertussis antigen) 5 mcg / 0.5 mL + pertactin (b. pertussis virulence factor) 3 mcg / 0.5 mL + pertussis toxoid 10 mcg / 0.5 mL + polyribose ribitol phosphate polysaccharide (prp - hib) 10 mcg / 0.5 mL + tetanus protein 30 mcg / 0.5 mL + tetanus toxoid 5 LF / 0.5 mL liquid for injection,Sanofi Pasteur Limited,23701000087103,Pediatric vaccine product containing only diphtheria standard dose + tetanus + acellular pertussis standard dose + Haemophilus influenzae type b antigens (medicinal product),Diphtheria + Tetanus + Pertussis + Haemophilus influenzae type b pediatric,DTaP-Hib ped,940021261000087101,Vaccine product containing only acellular pertussis + diphtheria + Haemophilus influenzae type b + tetanus antigens (medicinal product),Diphtheria + Tetanus + aPertussis + Haemophilus influenzae type b,D/dTaP/p-Hib,J07AG52,"hemophilus influenzae b, combinations with pertussis and toxoids",DTaP-Hib ACTacel SP,Cancelled pre market,Added,2023-09-08,https://pdf.hres.ca/dpd_pm/00015724.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62115
02238684,Health_Canada,02238684,,Actacel Hybrid,23711000087101,ACTacel powder and diluent for solution for injection Sanofi Pasteur Limited (real clinical drug),liquid,intramuscular,733026001,Vial (unit of presentation),,8,diphtheria toxoid 15 LF / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 20 mcg / 0.5 mL + fimbriae (b. pertussis antigen) 5 mcg / 0.5 mL + pertactin (b. pertussis virulence factor) 3 mcg / 0.5 mL + pertussis toxoid 20 mcg / 0.5 mL + polyribose ribitol phosphate polysaccharide (prp - hib) 10 mcg / 0.5 mL + tetanus protein 20 mcg / 0.5 mL + tetanus toxoid 5 LF / 0.5 mL liquid for injection,Sanofi Pasteur Limited,23701000087103,Pediatric vaccine product containing only diphtheria standard dose + tetanus + acellular pertussis standard dose + Haemophilus influenzae type b antigens (medicinal product),Diphtheria + Tetanus + Pertussis + Haemophilus influenzae type b pediatric,DTaP-Hib ped,940021261000087101,Vaccine product containing only acellular pertussis + diphtheria + Haemophilus influenzae type b + tetanus antigens (medicinal product),Diphtheria + Tetanus + aPertussis + Haemophilus influenzae type b,D/dTaP/p-Hib,J07AG52,"hemophilus influenzae b, combinations with pertussis and toxoids",DTaP-Hib ACTacel HYBRID SP,Cancelled pre market,Added,2023-09-08,https://pdf.hres.ca/dpd_pm/00015724.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62116
01959034,Health_Canada,01959034,66128205,Act-Hib,7031000087105,Act-HIB 10 micrograms per 0.5 milliliter powder and diluent for solution for injection Sanofi Pasteur Limited (real clinical drug),kit AND powder for solution,intramuscular,733026001,Vial (unit of presentation),,2,haemophilus influenzae type b-prp 10 mcg / 0.5 mL with tetanus protein 30 mcg / 0.5 mL kit (powder for solution) for injection,Sanofi Pasteur Limited,2041000221105,Vaccine product containing only Haemophilus influenzae type b capsular polysaccharide antigen conjugated (medicinal product),Conjugated Haemophilus influenza type b,Hib-C,871764007,Vaccine product containing only Haemophilus influenzae type B antigen (medicinal product),Haemophilus influenzae type b,Hib,J07AG01,"hemophilus influenzae b, purified antig. conjugated",Hib Act-HIB SP,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00051009.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13140
02240255,Health_Canada,02240255,66124758,Adacel,7431000087103,ADACEL suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),,6,diphtheria toxoid 2 LF / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 5 mcg / 0.5 mL + fimbriae types 2 and 3 (fim - b. pertussis antigen) 5 mcg / 0.5 mL + pertactin (b. pertussis virulence factor) 3 mcg / 0.5 mL + pertussis toxoid 2.5 mcg / 0.5 mL + tetanus toxoid 5 LF / 0.5 mL suspension for injection,Sanofi Pasteur Limited,7851000087109,Adult vaccine product containing only tetanus + diphtheria low dose + acellular pertussis low dose antigens (medicinal product),Tetanus + Diphtheria + Pertussis adult,Tdap,2051000221107,Adult vaccine product containing only acellular Bordetella pertussis and Clostridium tetani toxoid and Corynebacterium diphtheriae toxoid antigens (medicinal product),Tetanus + Diphtheria + Pertussis,Tdap,J07AJ52,"pertussis, purified antigen, comb. with toxoids",Tdap ADACEL SP,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00063970.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63789
02352044,Health_Canada,02352044,66128131,Adacel-Polio,7481000087104,ADACEL-POLIO suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),,9,diphtheria toxoid 2 LF / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 5 mcg / 0.5 mL + fimbriae types 2 and 3 (fim - b. pertussis antigen) 5 mcg / 0.5 mL + pertactin (b. pertussis virulence factor) 3 mcg / 0.5 mL + pertussis toxoid 2.5 mcg / 0.5 mL + poliovirus type 1 mahoney (inactivated) 29 unit / 0.5 mL + poliovirus type 2 mef1 (inactivated) 7 unit / 0.5 mL + poliovirus type 3 saukett (inactivated) 26 unit / 0.5 mL + tetanus toxoid 5 LF / 0.5 mL suspension for injection,Sanofi Pasteur Limited,7891000087104,Adult vaccine product containing only tetanus + diphtheria low dose + acellular pertussis low dose + inactivated human poliovirus antigens (medicinal product),Tetanus + Diphtheria + Pertussis + Polio adult,Tdap-IPV adult,871894009,Vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and low dose Corynebacterium diphtheriae and inactivated whole Human poliovirus antigens (medicinal product),Tetanus + Diphtheria + Pertussis + Polio,Tdap-IPV,J07CA02,diphtheria-pertussis-poliomyelitis-tetanus,Tdap-IPV ADACEL-POLIO SP,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00063970.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83726
02473283,Health_Canada,02473283,66127355,Afluria Tetra,24381000087107,AFLURIA TETRA 15 micrograms per 0.5 milliliter suspension for injection Seqirus Pty Ltd (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Single-dose prefilled syringe,4,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b (victoria) 15 mcg / 0.5 mL + haemagglutinin-strain b (yamagata) 15 mcg / 0.5 mL suspension for injection,Seqirus Pty Ltd,28181000087101,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus Victoria and Yamagata lineage standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B+YV unadjuvanted standard dose,Inf H1N1+H3N2+B+YV SD,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf AFLURIA TETRA SEQ -Single dose Pre-filled syringe,Dormant,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00062847.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96268
02473313,Health_Canada,02473313,66127355,Afluria Tetra,24381000087107,AFLURIA TETRA 15 micrograms per 0.5 milliliter suspension for injection Seqirus Pty Ltd (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Multidose vial,4,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b (victoria) 15 mcg / 0.5 mL + haemagglutinin-strain b (yamagata) 15 mcg / 0.5 mL suspension for injection,Seqirus Pty Ltd,28181000087101,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus Victoria and Yamagata lineage standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B+YV unadjuvanted standard dose,Inf H1N1+H3N2+B+YV SD,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf AFLURIA TETRA SEQ - Multi-dose vial,Dormant,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00062847.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96272
7581000087103,SNOMED-CT,,66124873,Agriflu,7581000087103,"Agriflu 15 micrograms per 0.5 milliliter suspension for injection Novartis Vaccines and Diagnostics, Inc. (real clinical drug)",,,,,,,,"Novartis Vaccines and Diagnostics, Inc.",28171000087103,Adjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B adjuvanted,Inf H1N1+H3N2+B adj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf Agriflu NVD,Cancelled,Added,2022-03-31,https://www.seqirus.ca/-/media/seqirus-canada/docs-en/2020-agriflu-product-monograph--revised-23oct2020.pdf,
02346850,Health_Canada,02346850,66124873,Agriflu,22971000087103,AGRIFLU 15 micrograms per 0.5 milliliter suspension for injection Seqirus UK Limited (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Single dose prefilled syringe,3,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b 15 mcg / 0.5 mL suspension for injection,Seqirus Uk Limited,28171000087103,Adjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B adjuvanted,Inf H1N1+H3N2+B adj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf AGRIFLU SEQ - Single dose pre-filled syringe,Cancelled pre market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00058069.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83225
02428881,Health_Canada,02428881,66124873,Agriflu,22971000087103,AGRIFLU 15 micrograms per 0.5 milliliter suspension for injection Seqirus UK Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Multi dose vial,3,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b 15 mcg / 0.5 mL suspension for injection,Seqirus Uk Limited,28171000087103,Adjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B adjuvanted,Inf H1N1+H3N2+B adj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf AGRIFLU SEQ - Multi-dose vial,Cancelled pre market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00058069.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91331
02502895,Health_Canada,02502895,,Anthim,SCT TBD 8,ANTHIM 100 milligrams per 1 milliter solution for injection Elusys Therapeutics Inc (real clinical drug),solution,intravenous,733026001,Vial (unit of presentation),,1,,"Elusys Therapeutics, Inc",780044006,Product containing only obiltoxaximab in parenteral dose form (medicinal product form),Antrax mAb obiltoxaximab,Anth mAb obiltoxaximab,SCT TBD 23,Product containing only Anthrax monoclonal antibody (medicinal product),Anthrax monoclonal antibody,Anth mAb,J06BC04,obiltoxaximab,Anth ANTHIM  ET,Restricted,Added,2023-06-23,https://pdf.hres.ca/dpd_pm/00057308.PDF,
02401886,Health_Canada,02401886,66128551,Arepanrix H5N1,57881000087106,AREPANRIX H5N1 3.75 micrograms per 0.5 milliliter suspension and emulsion for injection ID Biomedical Corporation of Quebec (real clinical drug),emulsion,intramuscular,733026001,Vial (unit of presentation),As03-adjuvanted h5n1 pandemic influenza vaccine,1,haemagglutinin-strain a (h5n1) 3.75 mcg / 0.5 mL emulsion for injection,Id Biomedical Corporation Of Quebec,1003499009,Vaccine product containing only Influenza A virus subtype H5N1 antigen (medicinal product),Influenza H5N1 vaccine,Inf H5N1,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf AREPANRIX H5N1 IDB,Marketed,Modified,2025-05-01,https://pdf.hres.ca/dpd_pm/00037980.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88676
02540207,Health_Canada,02540207,,Arexvy,51301000087102,AREXVY 120 micrograms per 0.5 milliliter powder and suspension for suspension for injection GlaxoSmithKline Inc. (real clinical drug),powder for suspension,intramuscular,733026001,Vial (unit of presentation),,1,respiratory syncytial virus prefusion f protein (rsvpref3) 120 mcg / 0.5 mL powder for suspension for injection,Glaxosmithkline Inc,61771000087101,Vaccine product containing only Human orthopneumovirus messenger ribonucleic acid (medicinal product),Respiratory syncytial virus recombinant,RSV recomb,51311000087100,Vaccine product containing only Human orthopneumovirus antigen (medicinal product),RSV antigen,RSV mRNA,J07BX05,respiratory syncytial virus vaccine,RSV Arexvy GSK,Marketed,Added,2023-11-08,https://pdf.hres.ca/dpd_pm/00071904.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102891
02237792,Health_Canada,02237792,66124760,Avaxim,6851000087107,AVAXIM 160 units per 0.5 milliliter suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),,1,"hepatitis a virus, inactivated 160 unit / 0.5 mL suspension for injection",Sanofi Pasteur Limited,19371000087102,Adult vaccine product containing only Hepatitis A virus regular strength antigen (medicinal product),Hepatitis A adult,HA adult,871751006,Vaccine product containing only Hepatitis A virus antigen (medicinal product),Hepatitis A,HA,J07BC02,"hepatitis a, inactivated, whole virus",HA AVAXIM SP,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00061302.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61149
02243741,Health_Canada,02243741,66124831,Avaxim - Pediatric,6861000087105,AVAXIM 80 units per 0.5 milliliter suspension for injection Sanofi Pasteur SA (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),,1,"hepatitis a vaccine, inactivated 80 unit / 0.5 mL suspension for injection",Sanofi Pasteur Limited,9811000087103,Pediatric vaccine product containing only Hepatitis A virus low strength antigen (medicinal product),Hepatitis A pediatric,HA ped,871751006,Vaccine product containing only Hepatitis A virus antigen (medicinal product),Hepatitis A,HA,J07BC02,"hepatitis a, inactivated, whole virus",HA AVAXIM - Pediatric SP,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00061173.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67674
19421000087106,SNOMED-CT,,,BabyBIG,19421000087106,BabyBIG [Botulism Immune Globulin Intravenous (Human) (BIG-IV)] 50 milligrams per milliliter powder for solution for infusion California Department of Public Health (real clinical drug),,,,,,,,California Department of Public Health,417004001,Product containing precisely botulism immunoglobulin 100 milligram/1 vial powder for conventional release solution for injection (clinical drug),Botulilsm immunoglobulin 100mg/vial intravenous,BIG-IV,416653007,Product containing botulism immunoglobulin (medicinal product),Botulism immunoglobulin,BIG,J06BA02,"immunoglobulins, normal human, for intravascular admininstration",BIG-IV BabyBIG CDPH,Special Access,Added,2022-03-31,https://www.infantbotulism.org/BabyBIG%20Package%20Insert%202016_09.pdf,
21941000087104,SNOMED-CT,,,BAT Cangene,21941000087104,"BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] solution for injection Cangene Corporation (real clinical drug)",,,,,,,,Cangene Corporation,21911000087100,Product containing only botulism antitoxin 7 serotypes (medicinal product),Botulism antitoxin heptavalent,BAT-7,86080005,Product containing botulinum antitoxin (medicinal product),Botulinum antitoxin,BAtx,J06AA04,botulinum antitoxin,BAtx BAT Cang,Special Access,Added,2022-03-31,https://www.fda.gov/media/85514/download,
23751000087102,SNOMED-CT,,,BAT Emergent,23751000087102,"BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] solution for injection Emergent BioSolutions Canada Inc. (real clinical drug)",,,,,,,,Emergent BioSolutions Canada Inc.,21911000087100,Product containing only botulism antitoxin 7 serotypes (medicinal product),Botulism antitoxin heptavalent,BAT-7,86080005,Product containing botulinum antitoxin (medicinal product),Botulinum antitoxin,BAtx,J06AA04,botulinum antitoxin,BAtx BAT EBS,Special Access,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00058874.PDF,
00075124,Health_Canada,00075124,,Bcg Vaccine (Freeze-Dried),7011000087100,BCG Vaccine 1.5 microgram per 0.1 milliliter powder and diluent for suspension for injection Sanofi Pasteur Limited (real clinical drug),powder for solution,intradermal,733026001,Vial (unit of presentation),,1,bacillus calmette-guerin (bcg) substrain connaught 0.1 mg / 0.1 mL intradermal powder for solution,Sanofi Pasteur Limited,319941000221104,Vaccine product containing only live attenuated Mycobacterium bovis antigen in parenteral dose form (medicinal product form),Bacillus Calmette Guerin parenteral,BCG-P,418268006,Product containing antigen of live attenuated Mycobacterium bovis (medicinal product),Bacillus Calmette Guerin,BCG,J07AN01,"tuberculosis, live attenuated",BCG Vaccine SP,Cancelled post market,Added,2022-03-31,,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=673
01914537,Health_Canada,01914537,,BCG Vaccine IDM,26521000087106,"BCG VACCINE 0.75 microgram per 1.0 milliliter liquid, powder for injection ID BIOMEDICAL COOPERATION OF QUEBEC (real clinical drug)",powder for solution AND liquid,intradermal,733026001,Vial (unit of presentation),,2,bacillus calmette-guerin bcg 0.75 mg / mL + water 2 ml / vial intradermal powder for solution or liquid,Id Biomedical Corporation Of Quebec,319941000221104,Vaccine product containing only live attenuated Mycobacterium bovis antigen in parenteral dose form (medicinal product form),Bacillus Calmette Guerin parenteral,BCG-P,418268006,Product containing antigen of live attenuated Mycobacterium bovis (medicinal product),Bacillus Calmette Guerin,BCG,J07AN01,"tuberculosis, live attenuated",BCG Vaccine IDM,Cancelled post market,Added,2024-11-24,,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11585
SCT TBD 30,SNOMED-CT,,,Beijing Vigoo Biological EV71,SCT TBD 30,BIEJING VIGOO BIOLOGICAL inactivated Enterovirus 71 C4 genogroup antigen vaccine,,,,,,,,Biejing Vigoo Biological,SCT TBD 33,Vaccine product containing inactivated Enterovirus 71 antigen,Enterovirus 71 inactivated antigen,EV17-IA,51591000087104,Vaccine product containing only Enterovirus A71 antigen (medicinal product),Enterovirus antigen,EV71,J07BX06,enterovirus 17 vaccines,EV17 VIGOO,International,Added,2024-06-03,,
02417030,Health_Canada,02417030,66128075,Bexsero,21671000087103,BEXSERO suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Multicomponent meningoc. b vaccine (r-dna adsorbed). 0.5ml pfs.,4,outer membrane vesicles (neisseria meningitidis group b nz98/254 strain) 25 mcg / 0.5 mL + recombinant neisseria meningitidis group b fhbp fusion protein 50 mcg / 0.5 mL + recombinant neisseria meningitidis group b nada protein 50 mcg / 0.5 mL + recombinant neisseria meningitidis group b nhba fusion protein 50 mcg / 0.5 mL suspension for injection,Glaxosmithkline Inc,1981000221108,Vaccine product containing only Neisseria meningitidis serogroup B antigen (medicinal product),Meningococcal B,Men-B,921000221108,Vaccine product containing only Neisseria meningitidis antigen (medicinal product),Meningococcal,Men,J07AH09,"meningococcus b, multicomponent vaccine",Men-B BEXSERO GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00060905.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90167
02537214,Health_Canada,02537214,,Beyfortus,58291000087105,BEYFORTUS 100 milligrams per 1 milliliter solution for injection syringe Sanofi Pasteur Limited (real clinical drug),solution,intramuscular,733020007,Syringe (unit of presentation),Single-use pre-filled syringe,1,nirsevimab 100 mg / 1 mL solution for injection,Sanofi Pasteur Limited,58531000087106,Product containing only nirsevimab (medicinal product),Respiratory syncytial virus mAb nirsevimab,RSV mAb nirsevimab,61231000087107,Product containing only monoclonal antibody to Orthopneumovirus hominis (medicinal product),RSV monoclonal antibody,RSV mAb,J06BD08,nirsevimab,RSVAb BEYFORTUS 100 mg/1 mL syringe SP,Marketed,Modified,2024-09-19,https://pdf.hres.ca/dpd_pm/00070439.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102595
02537206,Health_Canada,02537206,,Beyfortus,58301000087109,BEYFORTUS 50 milligrams per 0.5 milliliter solution for injection syringe Sanofi Pasteur Limited (real clinical drug),solution,intramuscular,733020007,Syringe (unit of presentation),Single-use pre-filled syringe,1,nirsevimab 50 mg / 0.5 mL solution for injection,Sanofi Pasteur Limited,58531000087106,Product containing only nirsevimab (medicinal product),Respiratory syncytial virus mAb nirsevimab,RSV mAb nirsevimab,61231000087107,Product containing only monoclonal antibody to Orthopneumovirus hominis (medicinal product),RSV monoclonal antibody,RSV mAb,J06BD08,nirsevimab,RSVAb BEYFORTUS 50 mg/0.5 mL syringe SP,Marketed,Modified,2024-09-19,https://pdf.hres.ca/dpd_pm/00070439.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102594
02483386,Health_Canada,02483386,,Biothrax,34631000087100,BioThrax 50 micrograms per 0.5 milliliter suspension for injection Emergent BioDefense Operations Lansing LLC (real clinical drug),suspension,"intramuscular, subcutaneous",733026001,Vial (unit of presentation),,1,,Emergent Biodefense Operations Lansing LLC,860818003,Vaccine product containing only Bacillus anthracis antigen (medicinal product),Bacillus anthracis antigen ,Anth-Ag,836384003,Vaccine product containing Bacillus anthracis antigen (medicinal product),Anthrax antigen,Anth Ag,J07AC01,anthrax antigen,Anth BioThrax EBOL,Restricted,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00059464.PDF,
02247600,Health_Canada,02247600,66127901,Boostrix,7441000087109,BOOSTRIX suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),,5,diphtheria toxoid 2 unit / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 8 mcg / 0.5 mL + pertactin (b. pertussis virulence factor) 2.5 mcg / 0.5 mL + pertussis toxoid 8 mcg / 0.5 mL + tetanus toxoid 20 unit / 0.5 mL suspension for injection,Glaxosmithkline Inc,7851000087109,Adult vaccine product containing only tetanus + diphtheria low dose + acellular pertussis low dose antigens (medicinal product),Tetanus + Diphtheria + Pertussis adult,Tdap,2051000221107,Adult vaccine product containing only acellular Bordetella pertussis and Clostridium tetani toxoid and Corynebacterium diphtheriae toxoid antigens (medicinal product),Tetanus + Diphtheria + Pertussis,Tdap,J07AX,other bacterial vaccines,Tdap BOOSTRIX GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00062364.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71860
02312557,Health_Canada,02312557,66128094,Boostrix-Polio,7491000087102,BOOSTRIX-POLIO suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),,8,diphtheria toxoid adsorbed 2.5 LF / 0.5 mL + filamentous haemagglutinin adsorbed 8 mcg / 0.5 mL + inactivated poliovirus type i 40 D / 0.5 mL + inactivated poliovirus type ii 8 D / 0.5 mL + inactivated poliovirus type iii 32 D / 0.5 mL + pertactin adsorbed 2.5 mcg / 0.5 mL + pertussis toxoid adsorbed 8 mcg / 0.5 mL + tetanus toxoid adsorbed 5 LF / 0.5 mL suspension for injection,Glaxosmithkline Inc,7891000087104,Adult vaccine product containing only tetanus + diphtheria low dose + acellular pertussis low dose + inactivated human poliovirus antigens (medicinal product),Tetanus + Diphtheria + Pertussis + Polio adult,Tdap-IPV adult,871894009,Vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and low dose Corynebacterium diphtheriae and inactivated whole Human poliovirus antigens (medicinal product),Tetanus + Diphtheria + Pertussis + Polio,Tdap-IPV,J07CA02,diphtheria-pertussis-poliomyelitis-tetanus,Tdap-IPV BOOSTRIX-POLIO GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00062367.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79806
19361000087106,SNOMED-CT,,,Botulism Antitoxin Behring,19361000087106,Botulism Antitoxin Behring solution for infusion Novartis Vaccines and Diagnostics (real clinical drug),,,,,,,,Novartis Vaccine and Diagnostics,SCT TBD 4,Product containing only botulism antitoxin 3 serotypes (medicinal product),Botulism antitoxin trivalent,BAT-3,86080005,Product containing botulinum antitoxin (medicinal product),Botulinum antitoxin,BAtx,J06AA04,botulinum antitoxin,BAtx Botulism Antitoxin Behring NVD,Special Access,Added,2022-03-31,https://www.hse.ie/eng/health/immunisation/hcpinfo/vaccineordering/botulismspc.pdf,
02549891,Health_Canada,02549891,,Capvaxive,60601000087107,CAPVAXIVE 0.5 milliliter solution for injection Merck Canada Inc. (real clinical drug),solution,intramuscular,733020007,Syringe (unit of presentation),Single-dose prefilled syringe,22,corynebacterium diphtheriae crm-197 protein 65 mcg / 0.5 mL + pneumococcal polysaccharide serotype 10a 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 11a 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 12f 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 15a 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 16f 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 17f 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 19a 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 20a 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 22f 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 23a 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 23b 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 24f 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 3 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 31 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 33f 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 35b 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 6a 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 7f 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 8 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 9n 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype deoac15b 4 mcg / 0.5 mL solution for injection,Merck Canada Inc,60591000087104,"Vaccine product containing only Streptococcus pneumoniae Danish serotype 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B capsular polysaccharide antigens conjugated (medicinal product)",Pneumococcal conjugated 21 valent,Pneu-C-21,981000221107,Vaccine product containing only Streptococcus pneumoniae antigen (medicinal product),Pneumococcal,Pneu,J07AL02,"pneumococcus, purified polysacc.antigen conjugated",Pneu-C-21 CAPVAXIVE Merck,Marketed,Added,2024-09-19,https://pdf.hres.ca/dpd_pm/00076331.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103871
02342227,Health_Canada,02342227,66127902,Cervarix,7341000087101,CERVARIX 40 micrograms per 0.5 milliliter suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),,2,recombinant hpv type 16|1 protein 20 mcg / 0.5 mL + recombinant hpv type 18|1 protein 20 mcg / 0.5 mL suspension for injection,Glaxosmithkline Inc,7791000087109,Vaccine product containing only Human papillomavirus 2 serotypes antigens (medicinal product),Human Papillomavirus (HPV-2),HPV-2,911000221103,Vaccine product containing only Human papillomavirus antigen (medicinal product),Human Papillomavirus,HPV,J07BM02,"papillomavirus (human types 16,18)",HPV-2 CERVARIX GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00049796.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82773
SCT TBD 32,SNOMED-CT,,,Chinese Academy of Medical Sciences EV71,SCT TBD 32,CHINESE ACADEMY OF MEDICAL SCIENCES inactivated Enterovirus 17 C4 genogroup antigen vaccine,,,,,,,,Chinese Academy of Medical Sciences,SCT TBD 33,Vaccine product containing inactivated Enterovirus 71 antigen,Enterovirus 71 inactivated antigen,EV17-IA,51591000087104,Vaccine product containing only Enterovirus A71 antigen (medicinal product),Enterovirus antigen,EV71,J07BX06,enterovirus 17 vaccines,EV17 CAMS,International,Added,2024-06-03,,
02522454,Health_Canada,02522454,66128582,Comirnaty 10 mcg per 0.2 mL,33361000087101,COMIRNATY (original strain) messenger ribonucleic acid 10 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Orange cap vial (5 years to <12 years) after dilution contains 10 doses of 0.2 ml,1,tozinameran (ba.4/ba.5) 10 mcg / 0.2 mL suspension for injection,Biontech Manufacturing Gmbh,33581000087104,Pediatric vaccine product containing only Severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA Pediatric,COVID-19 mRNA Ped,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 COMIRNATY (original strain) 10 mcg/0.2 ml pediatric mRNA PB (Orange cap/Orange label) DILUTE PRIOR TO USE,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00067155.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101157
02530325,Health_Canada,02530325,66128582,Comirnaty 3 mcg per 0.2 mL,34611000087105,COMIRNATY (original strain) messenger ribonucleic acid 3 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Maroon cap vial (6 months to <5 years) after dilution contains 10 doses of 0.2 ml,1,tozinameran (ba.4/ba.5) 3 mcg / 0.2 mL suspension for injection,Biontech Manufacturing Gmbh,33581000087104,Pediatric vaccine product containing only Severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA Pediatric,COVID-19 mRNA Ped,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 COMIRNATY pediatric 3 mcg/0.2 ml mRNA PB,Cancelled post market,Added,2022-12-11,https://pdf.hres.ca/dpd_pm/00067155.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101951
02527863,Health_Canada,02527863,66128582,Comirnaty 30 mcg per 0.3 mL tris_sucrose,33881000087102,COMIRNATY (original strain) messenger ribonucleic acid 30 micrograms per 0.3 milliliter tris-sucrose formulation suspension for injection BioNTech Manufacturing GmbH (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Grey cap vial (12+ years) do not dilute contains 6 doses of 0.3 ml,1,tozinameran (ba.4/ba.5) 30 mcg / 0.3 mL suspension for injection,Biontech Manufacturing Gmbh,1119349007,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA,COVID-19 mRNA,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 COMIRNATY (original strain) tris-sucrose 30 mcg/0.3 ml 12yrs+ mRNA PB (Grey cap/Grey label) - DO NOT dilute,Cancelled post market,Modified,2022-11-24,https://pdf.hres.ca/dpd_pm/00067155.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101706
02509210,Health_Canada,02509210,66128582,Comirnaty 30 mcg per 0.3mL,28581000087106,COMIRNATY (original strain) messenger ribonucleic acid 30 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Purple cap vial (12+ years) after dilution contains 6 doses of 0.3 ml,1,tozinameran (ba.4/ba.5) 30 mcg / 0.3 mL suspension for injection,Biontech Manufacturing Gmbh,1119349007,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA,COVID-19 mRNA,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 COMIRNATY (original strain) 30 mcg/0.3 ml 12+ mRNA PB (Purple cap/Purple label) DILUTE BEFORE USE,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00067155.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99852
02541858,Health_Canada,02541858,66128582,Comirnaty KP.2 10 mcg per 0.3 mL,60841000087109,COMIRNATY messenger ribonucleic acid 10 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Single dose vial and multidose vial,1,omicron s-protein mrna (kp.2) 10 mcg / 0.3 mL suspension for injection,Biontech Manufacturing Gmbh,33581000087104,Pediatric vaccine product containing only Severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA Pediatric,COVID-19 mRNA Ped,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 COMIRNATY  5-11yrs 10 mcg/0.3 mL mRNA PB,Marketed,Modified,2024-12-14,https://pdf.hres.ca/dpd_pm/00072622.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103046
02552078,Health_Canada,02552078,66128582,Comirnaty KP.2 3 mcg per 0.3 mL,61431000087108,COMIRNATY messenger ribonucleic acid 3 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Multidose vial,1,omicron s-protein mrna (kp.2) 3 mcg / 0.3 mL suspension for injection,Biontech Manufacturing Gmbh,33581000087104,Pediatric vaccine product containing only Severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA Pediatric,COVID-19 mRNA Ped,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 COMIRNATY 6mo-4yrs 3 mcg/0.3 mL mRNA PB,Approved,Modified,2024-12-14,https://pdf.hres.ca/dpd_pm/00077149.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104076
02541823,Health_Canada,02541823,66128582,Comirnaty KP.2 30 mcg per 0.3 mL,60681000087100,COMIRNATY messenger ribonucleic acid 30 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Single dose vial and multidose vial,1,omicron s-protein mrna (kp.2) 30 mcg / 0.3 mL suspension for injection,Biontech Manufacturing Gmbh,1119349007,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA,COVID-19 mRNA,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 COMIRNATY 12yrs+ 30 mcg/0.3mL mRNA PB,Marketed,Modified,2024-12-14,https://pdf.hres.ca/dpd_pm/00072622.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103044
02552035,Health_Canada,02552035,66128582,Comirnaty KP.2 30 mcg per 0.3 mL,60681000087100,COMIRNATY messenger ribonucleic acid 30 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Prefilled syringe,1,omicron s-protein mrna (kp.2) 30 mcg / 0.3 mL suspension for injection,Biontech Manufacturing Gmbh,1119349007,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA,COVID-19 mRNA,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 COMIRNATY 12yrs+ 30 mcg/0.3 mL mRNA PB,Marketed,Modified,2024-12-14,https://pdf.hres.ca/dpd_pm/00077149.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104073
02541831,Health_Canada,02541831,66128582,Comirnaty Omicron Xbb.1.5,51621000087101,COMIRNATY Omicron XBB.1.5 messenger ribonucleic acid 10 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),2.25 ml multidose vial,1,raxtozinameran (omicron xbb.1.5) 10 mcg / 0.2 mL suspension for injection,Biontech Manufacturing Gmbh,33581000087104,Pediatric vaccine product containing only Severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA Pediatric,COVID-19 mRNA Ped,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 COMIRNATY Omicron XBB.1.5 Pediatric 10 mcg/0.2 mL mRNA PB,Cancelled pre market,Added,2023-11-08,https://pdf.hres.ca/dpd_pm/00072622.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103045
02541866,Health_Canada,02541866,66128582,Comirnaty Omicron Xbb.1.5,51511000087105,COMIRNATY Omicron XBB.1.5 messenger ribonucleic acid 3 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),2.25 ml multidose vial,1,raxtozinameran (omicron xbb.1.5) 3 mcg / 0.2 mL suspension for injection,Biontech Manufacturing Gmbh,33581000087104,Pediatric vaccine product containing only Severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA Pediatric,COVID-19 mRNA Ped,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 COMIRNATY Omicron XBB.1.5 3 mcg/0.2 mL mRNA PB,Cancelled post market,Added,2023-11-08,https://pdf.hres.ca/dpd_pm/00072622.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103047
02541025,Health_Canada,02541025,66128582,Comirnaty Original & Omicron BA.4/BA.5,38821000087105,COMIRNATY Original & Omicron BA.4/BA.5 messenger ribonucleic acid 3 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),2.25 ml multidose vial,2,famtozinameran (ba.4/ba.5) 1.5 mcg / 0.2 mL + tozinameran (ba.4/ba.5) 1.5 mcg / 0.2 mL suspension for injection,Biontech Manufacturing Gmbh,33581000087104,Pediatric vaccine product containing only Severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA Pediatric,COVID-19 mRNA Ped,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 COMIRNATY Original & Omicron BA.4/BA.5 pediatric 3 mcg/0.2mL mRNA PB,Cancelled pre market,Added,2024-04-03,https://pdf.hres.ca/dpd_pm/00072465.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102970
02533197,Health_Canada,02533197,66128582,Comirnaty Original & Omicron Ba.4/Ba.5 10 mcg per 0.2 mL,37701000087106,COMIRNATY Original & Omicron BA.4/BA.5 messenger ribonucleic acid 10 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),1.3 ml multidose vial,2,famtozinameran (ba.4/ba.5) 5 mcg / 0.2 mL + tozinameran (ba.4/ba.5) 5 mcg / 0.2 mL suspension for injection,Biontech Manufacturing Gmbh,33581000087104,Pediatric vaccine product containing only Severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA Pediatric,COVID-19 mRNA Ped,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 COMIRNATY Original & Omicron BA.4/BA.5 30 mcg/0.3 mL mRNA PB,Cancelled post market,Added,2022-12-11,https://pdf.hres.ca/dpd_pm/00068639.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102220
02531461,Health_Canada,02531461,66128582,Comirnaty Original & Omicron BA.4/BA.5 30 mcg per 0.3 mL,37691000087106,COMIRNATY Original & Omicron BA.4/BA.5 messenger ribonucleic acid 30 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),2.25 ml multidose vial and 0.48ml single use vial,2,famtozinameran (ba.4/ba.5) 15 mcg / 0.3 mL + tozinameran (ba.4/ba.5) 15 mcg / 0.3 mL suspension for injection,Biontech Manufacturing Gmbh,1119349007,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA,COVID-19 mRNA,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 COMIRNATY Original & Omicron BA.4/BA.5 30 mcg/0.3 mL mRNA PB,Cancelled post market,Added,2022-11-20,https://pdf.hres.ca/dpd_pm/00067598.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102060
02532018,Health_Canada,02532018,66128582,Comirnaty Original/Omicron Ba.1,37871000087108,COMIRNATY Original / Omicron BA.1 messenger ribonucleic acid 30 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),2.25 ml multidose vial,2,riltozinameran (ba.1) 15 mcg / 0.3 mL + tozinameran (ba.4/ba.5) 15 mcg / 0.3 mL suspension for injection,Biontech Manufacturing Gmbh,1119349007,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA,COVID-19 mRNA,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 COMIRNATY Original / Omicron BA.1 30 mcg/0.3 mL mRNA PB,Cancelled pre market,Added,2022-11-20,https://pdf.hres.ca/dpd_pm/00067818.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102108
23771000087108,SNOMED-CT,,,Comvax,23771000087108,COMVAX 7.5 micrograms and 5 micrograms per 0.5 milliliter suspension for injection Merck & Co. Inc. (real clinical drug),,,,,,,,Merck & Co. Inc.,871806004,Vaccine product containing only Haemophilus influenzae type b and Hepatitis B virus antigens (medicinal product),Hib - Haemophilus influenzae type b + Hepatitis B pediatric,HIB-HB ped,871806004,Vaccine product containing only Haemophilus influenzae type B and Hepatitis B virus antigens (medicinal product),Hib - Haemophilus influenzae type b + Hepatitis B,Hib-HB,J07CA08,haemophilus influenzae b and hepatitis b,Hib-HB COMVAX MCI,International,Added,2022-03-31,https://www.drugs.com/pro/comvax-vaccine.html,
31431000087100,SNOMED-CT,,,Convidecia,31431000087100,Convidecia COVID-19 non-replicating vector vaccine (real medicinal product),,,,,,,,CanSino Biologic,29061000087103,Vaccine product containing only recombinant non-replicating viral vector encoding Severe acute respiratory syndrome coronavirus 2 spike protein (medicinal product),COVID-19 non-replicating vector,COVID-19 NRV,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN02,"covid-19, viral vector, non-replicating",COVID-19 Convidecia,International,Added,2022-03-31,https://www.who.int/news-room/feature-stories/detail/the--cansino-biologics-ad5-ncov-s--recombinant---covid-19-vaccine--what-you-need-to-know,
47591000087109,SNOMED-CT,,,Corbevax,47591000087109,CORBEVAX recombinant spike protein 0.5 milliliter suspension for injection Biological E. Limited (real clinical drug),,,733026001,Vial (unit of presentation),,,,Biological E Limited,1162643001,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN04,covid-19 protein subunit,COVID-19 CORBEVAX,International,Added,2024-04-03,"https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadSmPC/2.%20Corbevax%20vaccine%20SmPC,%20factsheet%205%20years%20and%20above.pdf",
31311000087104,SNOMED-CT,,,CoronaVac,31311000087104,CoronaVac COVID-19 whole inactivated virus vaccine (real medicinal product),,,,,,,,Sinovac Biotech Limited,1157024006,Vaccine product containing only inactivated whole severe acute respiratory syndrome coronavirus 2 antigen (medicinal product),COVID-19 whole inactivated virus,COVID-19 WIV,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN03,"covid-19, inactivated virus",COVID-19 CoronaVac,International,Added,2022-03-31,https://extranet.who.int/pqweb/vaccines/who-recommendation-sinovac-covid-19-vaccine-vero-cell-inactivated-coronavac,
33211000087105,SNOMED-CT,,,Covaxin,33211000087105,COVAXIN COVID-19 whole inactivated virus vaccine (real medicinal product),,,,,,,,Bharat Biotech International Ltd.,1157024006,Vaccine product containing only inactivated whole severe acute respiratory syndrome coronavirus 2 antigen (medicinal product),COVID-19 whole inactivated virus,COVID-19 WIV,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN03,"covid-19, inactivated virus",COVID-19 COVAXIN,International,Added,2022-03-31,https://extranet.who.int/pqweb/vaccines/who-recommendation-bharat-biotech-international-ltd-covid-19-vaccine-whole-virion,
02521326,Health_Canada,02521326,,Covifenz,30151000087105,COVIFENZ virus-like particle 3.75 micrograms per 0.5 milliliter emulsion for injection Medicago Inc. (real clinical drug),emulsion,intramuscular,733026001,Vial (unit of presentation),Vial contains 10 doses of 0.5 ml,1,virus-like particles (vlp) of sars-cov-2 spike protein 3.75 mcg / 0.5 mL emulsion for injection,Medicago Inc,30141000087107,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 virus-like particle antigen (medicinal product),COVID-19 virus-like particle,COVID-19 VLP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN04,"covid-19, protein subunit",COVID-19 COVIFENZ VLP MED,Cancelled pre market,Added,2022-11-24,https://pdf.hres.ca/dpd_pm/00064803.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101052
33401000087107,SNOMED-CT,,,COVIran Barekat,33401000087107,COVIran Barekat COVID-19 whole inactivated virus vaccine (real medicinal product),,,,,,,,Shifa Pharmed Industrial Group,1157024006,Vaccine product containing only inactivated whole severe acute respiratory syndrome coronavirus 2 antigen (medicinal product),COVID-19 whole inactivated virus,COVID-19 WIV,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN03,"covid-19, inactivated virus",COVID-19 COVIran Barekat,International,Added,2022-03-31,https://covid19.trackvaccines.org/vaccines/83/,
02512947,Health_Canada,02512947,66127322,Covishield,28961000087105,COVISHIELD non-replicant vector 0.5 milliliter solution for injection Verity Pharmaceuticals Inc. (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),Vial contains 10 doses of 0.5ml,1,chadox1-s [recombinant] 50000000000 vaginal pessary / 0.5 mL solution for injection,Verity Pharmaceuticals Inc.,29061000087103,Vaccine product containing only recombinant non-replicating viral vector encoding severe acute respiratory syndrome coronavirus 2 spike protein (medicinal product),COVID-19 non-replicating vector,COVID-19 NRV,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN02,"covid-19, viral vector, non-replicating",COVID-19 COVISHIELD VP - Multi-dose vial,Authorization by interim order expired,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00062430.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100219
33411000087109,SNOMED-CT,,,CoviVac,33411000087109,CoviVac COVID-19 whole inactivated virus vaccine (real medicinal product),,,,,,,,Chumakov Center,1157024006,Vaccine product containing only inactivated whole severe acute respiratory syndrome coronavirus 2 antigen (medicinal product),COVID-19 whole inactivated virus,COVID-19 WIV,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN03,"covid-19, inactivated virus",COVID-19 CoviVac CC,International,Added,2022-11-20,https://covid19.trackvaccines.org/vaccines/107/,
34921000087108,SNOMED-CT,,,Covovax,34921000087108,COVOVAX COVID-19 recombinant spike protein vaccine (real medicinal product),,,,,,,,Serum Institute of India,1162643001,Vaccine product containing only Severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN04,covid-19 protein subunit,COVID-19 COVOVAX SII,International,Added,2022-11-20,https://extranet.who.int/pqweb/vaccines/who-recommendation-siipl-covid-19-vaccine-rs-proteinnanoparticle,
33221000087102,SNOMED-CT,,,CureVac,33221000087102,CureVac COVID-19 messenger ribonucleic acid vaccine (real medicinal product),,,,,,,,CureVac N.V.,1119349007,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA,COVID-19 mRNA,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 mRNA CureVac,International,Added,2022-03-31,https://covid19.trackvaccines.org/vaccines/11/,
02231962,Health_Canada,02231962,,Cytogam,57901000087109,Cytogam 50 milligrams per milliliter solution for infusion KI BioPharma LLC (real clinical drug),solution,intravenous,733026001,Vial (unit of presentation),Also known as cytomegalovirus immune globulin (human),1,cytomegalovirus immunoglobulin (human) 2500 mg / 50 mL solution for injection,Ki Biopharma Llc,871744002,Product containing only Cytomegalovirus antibody in parenteral dose form (medicinal product form),Cytomegalovirus immunoglobulin parenteral,CMVIg,9778000,Product containing Cytomegalovirus antibody (medicinal product),CMVIg,CMVIg,J06BB09,cytomegalovirus immunoglobulin,CMVIg Cytogam KIB,Marketed,Modified,2024-09-19,https://pdf.hres.ca/dpd_pm/00053789.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51418
SCT TBD 24,SNOMED-CT,,,Dengvaxia,SCT TBD 24,DENGVAXIA tetravalent live-attenuated dengue virus vaccine (real medicinal product),,,,,,,,Sanofi Pasteur Ltd,SCT TBD 25,Vaccine product containing only live-attenuated dengue virus 4 antigen (medicinal product),Dengue live attenuated - 4,Deng-LA-4,871720004,Vaccine product containing only Dengue virus antigen (medicinal product),Dengue,Deng,J07BX04,dengue virus vaccines,Dengue DENGVAXIA,International,Added,2023-06-24,https://www.sanofi.com.sg/dam/jcr:97425977-7d65-4f3c-ad5e-dad142bf0f80/Dengvaxia%20SG%201022.pdf,
19431000087108,SNOMED-CT,,,Diphtheria antitoxin,19431000087108,Diphtheria antitoxin (equine) 170 milligrams per milliliter solution for injection Institute of Immunology Inc. (real clinical drug),,,,,,,,Institute of Immunology Inc.,871550005,Product containing only equine diphtheria antitoxin in parenteral dose form (medicinal product form),Diphtheria equine antitoxin,Datx-e,77048008,Product containing diphtheria antitoxin (medicinal product),Diphtheria antitoxin,DAtx,J06AA01,diphtheria antitoxin,DAtx Diphtheria antitoxin IOI,Cancelled,Added,2022-03-31,https://www.peelregion.ca/health/professionals/pdfs/diphtheria-antitoxin-product-monograph.pdf,
30901000087107,SNOMED-CT,,,Diphtheria Antitoxin,30901000087107,Diphtheria Antitoxin (DAT) 1000 international units per milliliter solution for injection Instituto Butantan Brasil (real clinical drug),,,,,,,,Instituto Butantan Brasil,871550005,Product containing only equine diphtheria antitoxin in parenteral dose form (medicinal product form),Diphtheria equine antitoxin,Datx-e,77048008,Product containing diphtheria antitoxin (medicinal product),Diphtheria antitoxin,DAtx,J06AA01,diphtheria antitoxin,DAtx Diphtheria Antitoxin (DAT) IBB,Special Access,Added,2022-03-31,https://www.cdc.gov/diphtheria/downloads/protocol.pdf,
00454591,Health_Canada,00454591,,Diphtheria Antitoxin (Equine),19301000087107,Diphtheria Antitoxin B.P. 1000 international units per milliliter solution for injection VINS Bioproducts Limited (real clinical drug),liquid,intramuscular OR intravenous,733026001,Vial (unit of presentation),,1,diphtheria antitoxin 20000 unit / vial liquid for injection,Aventis Pasteur Limited,871550005,Product containing only equine diphtheria antitoxin in parenteral dose form (medicinal product form),Diphtheria equine antitoxin,Datx-e,77048008,Product containing diphtheria antitoxin (medicinal product),Diphtheria antitoxin,DAtx,J06AA01,diphteria antitoxin,DAtx Diphtheria Antitoxin B.P. VINS,Cancelled post market,Added,2022-11-24,,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65797
02247208,Health_Canada,02247208,,Dukoral,24201000087108,DUKORAL oral suspension Valneva Sweden AB (real clinical drug),suspension,oral,733026001,Vial (unit of presentation),,5,"recombinant cholera toxin b subunit 1 mg / vial + vibrio cholerae inaba 48 classical biotype, heat inactivated 31250000000 cells / vial + vibrio cholerae inaba 6973 el tor biotype, formalin inactivated 31250000000 cells / vial + vibrio cholerae ogawa 50 classical biotype, formalin inactivated 31250000000 cells / vial + vibrio cholerae ogawa 50 classical biotype, heat inactivated 31250000000 cells / vial oral suspension",Valneva Sweden Ab,7721000087106,Vaccine product containing only inactivated whole Vibrio cholerae and Vibrio cholerae recombinant toxin B subunit antigens in oral dose form (medicinal product form),Cholera + Echoli Oral,Chol-Ecol-O,991000221105,Vaccine product containing only Vibrio cholerae antigen (medicinal product),Cholera,Chol,J07AE01,"cholera, inactivated, whole cell",Chol-Ecol-O DUKORAL VAL,Marketed,Modified,2024-09-19,https://pdf.hres.ca/dpd_pm/00063971.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71450
02296454,Health_Canada,02296454,66124764,Engerix-B,6921000087107,Engerix B 10 micrograms per 0.5 milliliter suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),,1,hepatitis b surface antigen (recombinant) 10 mcg / 0.5 mL suspension for injection,Glaxosmithkline Inc,9831000087108,Pediatric vaccine product containing only Hepatitis B virus low strength antigen (medicinal product),Hepatitis B pediatric,HB ped,871822003,Vaccine product containing only Hepatitis B virus antigen (medicinal product),Hepatitis B,HB,J07BC01,"hepatitis b, purified antigen",HB ENGERIX B pediatric GSK,Cancelled post market,Added,2024-04-03,https://pdf.hres.ca/dpd_pm/00051170.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78178
02487020,Health_Canada,02487020,66124764,Engerix-B,6921000087107,Engerix B 10 micrograms per 0.5 milliliter suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Prefilled syringe,1,hepatitis b surface antigen (recombinant) 10 mcg / 0.5 mL suspension for injection,Glaxosmithkline Inc,9831000087108,Pediatric vaccine product containing only Hepatitis B virus low strength antigen (medicinal product),Hepatitis B pediatric,HB ped,871822003,Vaccine product containing only Hepatitis B virus antigen (medicinal product),Hepatitis B,HB,J07BC01,"hepatitis b, purified antigen",HB ENGERIX B pediatric GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00058559.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97717
01919431,Health_Canada,01919431,66128130,Engerix-B,6911000087104,Engerix B 20 micrograms per milliliter suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,,,,1,hepatitis b surface antigen (recombinant) 20 mcg / 1 mL suspension for injection,Glaxosmithkline Inc,8771000087109,Adult vaccine product containing only Hepatitis B virus regular strength antigen (medicinal product),Hepatitis B adult,HB adult,871822003,Vaccine product containing only Hepatitis B virus antigen (medicinal product),Hepatitis B,HB,J07BC01,"hepatitis b, purified antigen",HB ENGERIX B GSK,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00051170.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11742
02487039,Health_Canada,02487039,66128130,Engerix-B,6911000087104,Engerix B 20 micrograms per milliliter suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Prefilled syringe,1,hepatitis b surface antigen (recombinant) 20 mcg / 1 mL suspension for injection,Glaxosmithkline Inc,8771000087109,Adult vaccine product containing only Hepatitis B virus regular strength antigen (medicinal product),Hepatitis B adult,HB adult,871822003,Vaccine product containing only Hepatitis B virus antigen (medicinal product),Hepatitis B,HB,J07BC01,"hepatitis b, purified antigen",HB ENGERIX B GSK - Pre-filled syringe,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00058559.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97718
02239910,Health_Canada,02239910,,Epaxal,26541000087102,EPAXAL 500 radioimmunoassay units per 0.5 milliliter suspension for injection BERNA BIOTECH LIMITED (real clinical drug),liquid,intramuscular,733020007,Syringe (unit of presentation),,1,"hepatitis a vaccine, inactivated 500 unit / 0.5 mL liquid for injection",Berna Biotech Ltd,19371000087102,Adult vaccine product containing only Hepatitis A virus regular strength antigen (medicinal product),Hepatitis A adult,HA adult,871751006,Vaccine product containing only Hepatitis A virus antigen (medicinal product),Hepatitis A,HA,J07BC02,"hepatitis a, inactivated, whole virus",HA EPAXAL BB,Cancelled post market,Added,2022-03-31,,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63411
33421000087101,SNOMED-CT,,,EpiVacCorona,33421000087101,EpiVacCorona COVID-19 recombinant spike protein vaccine (real medicinal product),,,,,,,,Vektor State Research Center of Virology and Biotechnology,1162643001,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN04,covid-19 protein subunit,COVID-19 EpiVacCorona,International,Added,2022-03-31,https://covid19.trackvaccines.org/vaccines/32/,
02532603,Health_Canada,02532603,,Ervebo,45411000087107,ERVEBO 72 million plaque forming units per milliliter solution for injection Merck Canada Inc. (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),Single dose vial,1,"rvsv [delta] g-zebov-gp, live attenuated 72000000 PFU / mL solution for injection",Merck Canada Inc,45891000087103,Vaccine product containing only live attenuated Zaire ebolavirus antigen (medicinal product),Ebolavirus live attenuated,EbV-LA,871721000,Vaccine product containing only Ebolavirus antigen (medicinal product),Ebolavirus,EbV,J07BX02,ebola vaccines,EZV ERVEBO Merck,Approved,Added,2023-03-21,https://pdf.hres.ca/dpd_pm/00068254.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102162
02526271,Health_Canada,02526271,,Evusheld,SCT TBD 13,EVUSHELD Cilgavimab 150 milligrams per 1.5 milliliter AND Tixagevimab 150 milligrams per 1.5 milliliter Astazeneca Canada Inc. (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),1 vial tixagevimab / 1 vial cilgavimab,2,cilgavimab 150 mg / 1.5 mL + tixagevimab 150 mg / 1.5 mL solution for injection,Astrazeneca Canada Inc,SCT TBD 17,Product containing only tixagevimab and cilgavimab (medicinal product),COVID-19 monoclonal antibodies for prevention,COVID-19 mAbs Prev,SCT TBD 22,Product containing only COVID-19 monoclonal antibody (medicinal product),SARS-CoV-2 monoclonal antibody,Covid-19 mAb,J06BD03,tixagevimab and cilgavimab,COVID-19 TIXAGEVIMAB AND CILGAVIMAB AZC,Cancelled post market,Added,2023-06-23,https://pdf.hres.ca/dpd_pm/00071063.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101539
7591000087101,SNOMED-CT,,66124872,Fluad,7591000087101,"FLUAD 15 micrograms per 0.5 milliliter suspension for injection Novartis Vaccines and Diagnostics, Inc. (real clinical drug)",,,,,,,,"Novartis Vaccines and Diagnostics, Inc.",28171000087103,Adjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B adjuvanted,Inf H1N1+H3N2+B adj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FLUAD NVD,Cancelled,Added,2022-03-31,http://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Epid/CD%20Manual/Chapter%202%20-%20Imms/Part4/Influenza_Fluad.pdf,
02362384,Health_Canada,02362384,66124872,Fluad,22981000087101,FLUAD 15 micrograms per 0.5 milliliter suspension for injection Seqirus UK Limited (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Single-dose glass prefilled 1ml syringe containing 1 dose of 0.5ml,3,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b 15 mcg / 0.5 mL suspension for injection,Seqirus Uk Limited,28171000087103,Adjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B adjuvanted,Inf H1N1+H3N2+B adj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FLUAD SEQ,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00067335.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84739
02434881,Health_Canada,02434881,66124872,Fluad Pediatric,28391000087101,FLUAD Pediatric 7.5 micrograms per 0.25 milliliter suspension for injection Seqirus UK Limited (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),0.25ml single dose prefilled syringe,3,haemagglutinin-strain a (h1n1) 7.5 mcg / 0.25 mL + haemagglutinin-strain a (h3n2) 7.5 mcg / 0.25 mL + haemagglutinin-strain b 7.5 mcg / 0.25 mL suspension for injection,Seqirus Uk Limited,28161000087107,Adjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus low dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B adjuvanted Pediatric,Inf H1N1+H3N2+B adj Pediatric,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FLUAD Pediatric SEQ,Dormant,Modified,2022-11-24,https://pdf.hres.ca/dpd_pm/00067335.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91919
02553708,Health_Canada,02553708,,Flucelvax,268981000087103,FLUCELVAX 15 micrograms per 0.5 milliliter suspension for injection Seqirus UK Limited (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Single use prefilled syringe,3,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b 15 mcg / 0.5 mL suspension for injection,Seqirus Uk Limited,28191000087104,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B unadjuvanted standard dose,Inf H1N1+H3N2+B unadj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FLUCELVAX SEQ Pre-filled syringe,Marketed,Added,2025-01-26,https://pdf.hres.ca/dpd_pm/00077953.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104261
02553716,Health_Canada,02553716,,Flucelvax,268981000087103,FLUCELVAX 15 micrograms per 0.5 milliliter suspension for injection Seqirus UK Limited (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Multidose vial,3,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b 15 mcg / 0.5 mL suspension for injection,Seqirus Uk Limited,28191000087104,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B unadjuvanted standard dose,Inf H1N1+H3N2+B unadj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FLUCELVAX SEQ Multi-dose vial,Approved,Added,2025-01-26,https://pdf.hres.ca/dpd_pm/00077953.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104262
02494248,Health_Canada,02494248,,Flucelvax Quad,28491000087107,FLUCELVAX QUAD 15 micrograms per 0.5 milliliter suspension for injection Seqirus UK Limited (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Single dose prefilled syringe,4,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b (victoria) 15 mcg / 0.5 mL + haemagglutinin-strain b (yamagata) 15 mcg / 0.5 mL suspension for injection,Seqirus Uk Limited,28181000087101,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus Victoria and Yamagata lineage standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B+YV unadjuvanted standard dose,Inf H1N1+H3N2+B+YV SD,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FLUCELVAX QUAD SEQ - Single dose pre-filled syringe,Dormant,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00062957.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98427
02494256,Health_Canada,02494256,,Flucelvax Quad,28491000087107,FLUCELVAX QUAD 15 micrograms per 0.5 milliliter suspension for injection Seqirus UK Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Multidose vial,4,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b (victoria) 15 mcg / 0.5 mL + haemagglutinin-strain b (yamagata) 15 mcg / 0.5 mL suspension for injection,Seqirus Uk Limited,28181000087101,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus Victoria and Yamagata lineage standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B+YV unadjuvanted standard dose,Inf H1N1+H3N2+B+YV SD,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FLUCELVAX QUAD SEQ - Multi-dose vial,Approved,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00062957.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98428
02420783,Health_Canada,02420783,66128005,Flulaval Tetra,20811000087102,FLULAVAL TETRA 15 micrograms per 0.5 milliliter suspension for injection ID Biomedical Corporation of Quebec (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),"Multi-dose vial, with preservative",4,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b (victoria) 15 mcg / 0.5 mL + haemagglutinin-strain b (yamagata) 15 mcg / 0.5 mL suspension for injection,Id Biomedical Corporation Of Quebec,28181000087101,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus Victoria and Yamagata lineage standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B+YV unadjuvanted standard dose,Inf H1N1+H3N2+B+YV SD,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen","Inf FLULAVAL TETRA IDB - Multi-dose vial, with preservative",Dormant,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00063338.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90535
02478978,Health_Canada,02478978,66128005,Flulaval Tetra,20811000087102,FLULAVAL TETRA 15 micrograms per 0.5 milliliter suspension for injection ID Biomedical Corporation of Quebec (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),"Single-dose pre-filled syringe, preservative-free",4,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b (victoria) 15 mcg / 0.5 mL + haemagglutinin-strain b (yamagata) 15 mcg / 0.5 mL suspension for injection,Id Biomedical Corporation Of Quebec,28181000087101,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus Victoria and Yamagata lineage standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B+YV unadjuvanted standard dose,Inf H1N1+H3N2+B+YV SD,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen","Inf FLULAVAL TETRA IDB - Single dose Pre-filled syringe, preservative-free",Approved,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00063338.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96969
02352621,Health_Canada,02352621,66127978,Flumist,7571000087100,FLUMIST 0.2 milliliter intranasal spray AstraZeneca Canada (real clinical drug),spray,nasal,733020007,Syringe (unit of presentation),,3,influenza virus type a (h1n1) 32000000 FFU / 0.2 mL + influenza virus type a (h3n2) 32000000 FFU / 0.2 mL + influenza virus type b 32000000 FFU / 0.2 mL nasal spray,Astrazeneca Canada Inc,28341000087108,Vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus live attenuated antigens in nasal dose form (medicinal product form),Influenza trivalent intranasal,LAIV-3,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB03,"influenza, live attenuated",Inf FLUMIST AZC,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00025175.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83789
02426544,Health_Canada,02426544,66128276,Flumist Quadrivalent,20741000087105,FLUMIST QUADRIVALENT 0.2 milliliter intranasal spray AstraZeneca Canada Inc. (real clinical drug),spray,nasal,733020007,Syringe (unit of presentation),"0.2ml prefilled, single-use glass sprayer",4,influenza virus type a (h1n1) 32000000 FFU / 0.2 mL + influenza virus type a (h3n2) 32000000 FFU / 0.2 mL + influenza virus type b (victoria) 32000000 FFU / 0.2 mL + influenza virus type b (yamagata) 32000000 FFU / 0.2 mL nasal spray,Astrazeneca Canada Inc,28201000087102,Vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus Victoria and Yamagata lineage live attenuated antigens in nasal dose form (medicinal product form),Influenza quadrivalent intranasal,LAIV-4-VY,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB03,"influenza, live attenuated",Inf FLUMIST QUADRIVALENT AZC,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00067353.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91111
02420686,Health_Canada,02420686,66124765,Fluviral,7541000087108,FLUVIRAL 15 micrograms per 0.5 milliliter suspension for injection ID Biomedical Corporation of Quebec (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),"Trivalent, split-virion, inactivated influenza vaccine",3,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b 15 mcg / 0.5 mL suspension for injection,Id Biomedical Corporation Of Quebec,28191000087104,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B unadjuvanted standard dose,Inf H1N1+H3N2+B unadj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FLUVIRAL IDB,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00063036.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90524
02445646,Health_Canada,02445646,,Fluzone High-Dose,21931000087105,FLUZONE High-Dose 60 micrograms per 0.5 milliliter suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Influenza virus vaccine trivalent types a and b (split virion).0.5 ml single-dose prefilled syringes,3,haemagglutinin-strain a (h1n1) 60 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 60 mcg / 0.5 mL + haemagglutinin-strain b 60 mcg / 0.5 mL suspension for injection,Sanofi Pasteur Limited,28221000087108,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus high dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B unadjuvanted high-dose,Inf H1N1+H3N2+B unadj HD,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FLUZONE High-Dose SP,Marketed,Added,2025-09-10,https://pdf.hres.ca/dpd_pm/00058074.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93092
02500523,Health_Canada,02500523,66127356,Fluzone High-Dose Quadrivalent,31571000087102,FLUZONE High-Dose Quadrivalent 60 micrograms per 0.7 milliliter suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Pre-filled syringe,4,haemagglutinin-strain a (h1n1) 60 mcg / 0.7 mL + haemagglutinin-strain a (h3n2) 60 mcg / 0.7 mL + haemagglutinin-strain b (victoria) 60 mcg / 0.7 mL + haemagglutinin-strain b (yamagata) 60 mcg / 0.7 mL suspension for injection,Sanofi Pasteur Limited,31581000087100,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus Victoria and Yamagata lineage high dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B+YV unadjuvanted high-dose,Inf H1N1+H3N2+B+YV HD,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FLUZONE High-Dose Quadrivalent SP,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00067331.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99020
02420643,Health_Canada,02420643,66128160,Fluzone Quadrivalent,20691000087107,FLUZONE Quadrivalent 15 micrograms per 0.5 milliliter suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),0.5 ml prefilled syringes. influenza virus vaccine quadrivalent types a & b (split virion),4,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b (victoria) 15 mcg / 0.5 mL + haemagglutinin-strain b (yamagata) 15 mcg / 0.5 mL suspension for injection,Sanofi Pasteur Limited,28181000087101,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus Victoria and Yamagata lineage standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B+YV unadjuvanted standard dose,Inf H1N1+H3N2+B+YV SD,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FLUZONE Quadrivalent SP - Pre-filled syringe,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00067329.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90522
02432730,Health_Canada,02432730,66128073,Fluzone Quadrivalent,20691000087107,FLUZONE Quadrivalent 15 micrograms per 0.5 milliliter suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),With preservative. 5ml multidose vial.,4,haemagglutinin-strain a (h1n1) 30 mcg / mL + haemagglutinin-strain a (h3n2) 30 mcg / mL + haemagglutinin-strain b (victoria) 30 mcg / mL + haemagglutinin-strain b (yamagata) 30 mcg / mL suspension for injection,Sanofi Pasteur Limited,28181000087101,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus Victoria and Yamagata lineage standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B+YV unadjuvanted standard dose,Inf H1N1+H3N2+B+YV SD,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FLUZONE Quadrivalent SP - Multi-dose vial,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00067329.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91717
02365707,Health_Canada,02365707,66128275,Fluzone Trivalent Subvirion,271421000087109,FLUZONE Trivalent 15 micrograms per 0.5 milliliter suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Influenza virus vaccine trivalent types a & b (split virion). 0.5ml pre-filled syringe,3,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b 15 mcg / 0.5 mL suspension for injection,Sanofi Pasteur Limited,28191000087104,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B unadjuvanted standard dose,Inf H1N1+H3N2+B unadj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FLUZONE SP,Marketed,Added,2024-09-19,https://pdf.hres.ca/dpd_pm/00075545.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85059
02365936,Health_Canada,02365936,66128275,Fluzone Trivalent Subvirion,271421000087109,FLUZONE Trivalent 15 micrograms per 0.5 milliliter suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Influenza virus vaccine trivalent types a & b (split virion).  5 ml multidose vial,3,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b 15 mcg / 0.5 mL suspension for injection,Sanofi Pasteur Limited,28191000087104,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B unadjuvanted standard dose,Inf H1N1+H3N2+B unadj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FLUZONE SP,Marketed,Added,2024-09-19,https://pdf.hres.ca/dpd_pm/00075545.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85079
02510561,Health_Canada,02510561,,Foclivia,45401000087105,FOCLIVIA 7.5 micrograms per 0.5 milliliter suspension for injection Seqirus UK Limited (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Pre-filled syringe,1,haemagglutinin-strain a (h5n1) 7.5 mcg / 0.5 mL suspension for injection,Seqirus Uk Limited,1003499009,Vaccine product containing only Influenza A virus subtype H5N1 antigen (medicinal product),Influenza H5N1 vaccine,Inf H5N1,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FOCLIVIA SEQ - Pre-filled syringe,Approved,Modified,2023-03-21,https://pdf.hres.ca/dpd_pm/00059552.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99978
02510588,Health_Canada,02510588,,Foclivia,45401000087105,FOCLIVIA 7.5 micrograms per 0.5 milliliter suspension for injection Seqirus UK Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Multi-dose vial,1,haemagglutinin-strain a (h5n1) 7.5 mcg / vial suspension for injection,Seqirus Uk Limited,1003499009,Vaccine product containing only Influenza A virus subtype H5N1 antigen (medicinal product),Influenza H5N1 vaccine,Inf H5N1,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf FOCLIVIA SEQ - Multi-dose vial,Approved,Modified,2023-03-21,https://pdf.hres.ca/dpd_pm/00059552.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99979
7021000087108,SNOMED-CT,,,Freeze-dried Glutamate BCG Vaccine Japan,7021000087108,BCG Freeze-dried Glutamate BCG Vaccine (Japan) 0.5 microgram per milliliter powder and diluent for suspension for injection Japan BCG Laboratory (real clinical drug),,,,,,,,Japan BCG Laboratory,319941000221104,Vaccine product containing only live attenuated Mycobacterium bovis antigen in parenteral dose form (medicinal product form),Bacillus Calmette Guerin parenteral,BCG-P,418268006,Product containing antigen of live attenuated Mycobacterium bovis (medicinal product),Bacillus Calmette Guerin,BCG,J07AN01,"tuberculosis, live attenuated",BCG Freeze-dried Glutamate BCG Vaccine Japan JBCG,Cancelled,Added,2022-03-31,https://id-ea.org/wp-content/uploads/2022/03/BCGFreezeDried_WHOPQ_PI.pdf,
02264625,Health_Canada,02264625,,Fsme-Immun,7211000087109,FSME-IMMUN 2.4 micrograms per 0.5 milliliter suspension for injection Baxter AG (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),,1,tick-borne encephalitis vaccine (inactivated) 2.4 mcg / 0.5 mL suspension for injection,Baxter Corporation,871719005,Vaccine product containing only Tick-borne encephalitis virus antigen (medicinal product),Tick-borne encephalitis Neudorfl,TBE-N,836403007,Vaccine product containing Tick-borne encephalitis virus antigen (medicinal product),Tick-borne encephalitis,TBE,J07BA01,"encephalitis, tick borne, inactivated, whole virus",TBE FSME-IMMUN BAG,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00013223.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75009
02486598,Health_Canada,02486598,,Gamastan,29721000087106,GamaSTAN 15 to 18 percent solution for injection Grifols Therapeutics Inc. (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),,1,immunoglobulin (human) 18 % solution for injection,Grifols Therapeutics Llc,780035005,Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form),Normal Human Immunoglobulin,Ig normal,333711001,Product containing human immunoglobulin (medicinal product),Immune globulin,Ig,J06BA01,"immunoglobulins, normal human, for extravasc. adm",Ig GamaSTAN Grif,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00050163.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97678
02230579,Health_Canada,02230579,,Gamastan S/D,19391000087103,GamaSTAN S/D 15 to 18 percent solution for injection Grifols Therapeutics Inc. (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),Medicinal ingredient also know as immune globulin (human),1,immunoglobulin (human) 18 % solution for injection,Grifols Therapeutics Llc,780035005,Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form),Normal Human Immunoglobulin,Ig normal,333711001,Product containing human immunoglobulin (medicinal product),Immune globulin,Ig,J06BA01,"immunoglobulins, normal human, for extravasc. adm",Ig GamaSTAN Grif,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00043801.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49688
02283190,Health_Canada,02283190,,Gardasil,7351000087103,GARDASIL 120 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),,4,recombinant hpv type 11|1 protein 40 mcg / 0.5 mL + recombinant hpv type 16|1 protein 40 mcg / 0.5 mL + recombinant hpv type 18|1 protein 20 mcg / 0.5 mL + recombinant hpv type 6|1 protein 20 mcg / 0.5 mL suspension for injection,Merck Canada Inc,7801000087108,Vaccine product containing only Human papillomavirus 4 serotypes antigens (medicinal product),Human Papillomavirus (HPV-4),HPV-4,911000221103,Vaccine product containing only Human papillomavirus antigen (medicinal product),Human Papillomavirus,HPV,J07BM01,"papillomavirus (human types 6,11,16,18)",HPV-4 GARDASIL MC,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00029689.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76882
02437058,Health_Canada,02437058,66128117,Gardasil 9,20871000087109,GARDASIL 9 270 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),0.5ml single-dose vials and prefilled syringes,9,recombinant hpv type 11|1 protein 40 mcg / 0.5 mL + recombinant hpv type 16|1 protein 60 mcg / 0.5 mL + recombinant hpv type 18|1 protein 40 mcg / 0.5 mL + recombinant hpv type 31|1 protein 20 mcg / 0.5 mL + recombinant hpv type 33|1 protein 20 mcg / 0.5 mL + recombinant hpv type 45|1 protein 20 mcg / 0.5 mL + recombinant hpv type 52|1 protein 20 mcg / 0.5 mL + recombinant hpv type 58|1 protein 20 mcg / 0.5 mL + recombinant hpv type 6|1 protein 30 mcg / 0.5 mL suspension for injection,Merck Canada Inc,20861000087100,Vaccine product containing only Human papillomavirus 9 serotypes antigens (medicinal product),Human Papillomavirus (HPV-9),HPV-9,911000221103,Vaccine product containing only Human papillomavirus antigen (medicinal product),Human Papillomavirus,HPV,J07BM03,"papillomavirus (human types 6,11,16,18,31,33,45,52,58)",HPV-9 GARDASIL 9 Merck,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00063713.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92136
02187078,Health_Canada,02187078,66124768,Havrix - Sus Im 1440 Elisa Units/Ml,6871000087101,Havrix 1440 ELISA units per milliliter suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,,,Single dose prefilled syringe,1,"hepatitis a virus, inactivated 1440 unit / mL suspension for injection",Glaxosmithkline Inc,19371000087102,Adult vaccine product containing only Hepatitis A virus regular strength antigen (medicinal product),Hepatitis A adult,HA adult,871751006,Vaccine product containing only Hepatitis A virus antigen (medicinal product),Hepatitis A,HA,J07BC02,"hepatitis a, inactivated, whole virus",HA HAVRIX 1440 GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00047293.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20256
02231056,Health_Canada,02231056,66124769,Havrix 720 Junior,6881000087104,Havrix 720 ELISA units per 0.5 milliliter suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,,,Single dose prefilled syringe,1,"hepatitis a virus, inactivated 720 unit / 0.5 mL suspension for injection",Glaxosmithkline Inc,9811000087103,Pediatric vaccine product containing only Hepatitis A virus low strength antigen (medicinal product),Hepatitis A pediatric,HA ped,871751006,Vaccine product containing only Hepatitis A virus antigen (medicinal product),Hepatitis A,HA,J07BC02,"hepatitis a, inactivated, whole virus",HA HAVRIX 720 Junior GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00039084.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50339
02290979,Health_Canada,02290979,,Hepagam B,57911000087106,HepaGam B 312 international units per milliliter liquid for injection KI BioPharma LLC (real clinical drug),solution,intravenous OR intramuscular,733026001,Vial (unit of presentation),"Hepatitis b immune globulin (human), strength > 312 iu/ml",1,hepatitis b immunoglobulin (human) 312 unit / mL solution for injection,Ki Biopharma Llc,784521005,Product containing precisely Hepatitis B surface antigen immunoglobulin 312 unit/1 milliliter conventional release solution for injection (clinical drug),Hepatitis B immunoglobulin 312 unit/1 ml,HBIg 312,9542007,Product containing Hepatitis B surface antigen immunoglobulin (medicinal product),Hepatitis B immunoglobulin,HBIg,J06BB04,hepatitis b immunoglobulin,HBIg HepaGam B KIB,Marketed,Modified,2024-09-19,https://pdf.hres.ca/dpd_pm/00042703.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77637
02239200,Health_Canada,02239200,66128170,Hiberix,7041000087104,Hiberix 10 micrograms per 0.5 milliliter powder and diluent for solution for injection GlaxoSmithKline Inc. (real clinical drug),powder for solution,intramuscular,733026001,Vial (unit of presentation),,1,haemophilus influenzae type b-prp and tetanus toxoid conjugate (prp-t) 10 mcg / 0.5 mL powder for solution for injection,Glaxosmithkline Inc,2041000221105,Vaccine product containing only Haemophilus influenzae type b capsular polysaccharide antigen conjugated (medicinal product),Conjugated Haemophilus influenza type b,Hib-C,871764007,Vaccine product containing only Haemophilus influenzae type B antigen (medicinal product),Haemophilus influenzae type b,Hib,J07AG51,"hemophilus influenzae b, combinations with toxoids",Hib HIBERIX GSK,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00053156.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62657
02520125,Health_Canada,02520125,,Hyperhep B,45881000087100,HyperHEP B 110 international units per 0.5 milliliter solution for injection Grifols Therapeutics Inc. (real clinical drug),solution,intramuscular,733020007,Syringe (unit of presentation),Prefilled syringe (neonatal),1,hepatitis b immunoglobulin (human) 110 unit / 0.5 mL solution for injection,Grifols Therapeutics Llc,SCT TBD 18,Product containing precisely Hepatitis B surface antigen immunoglobulin 110 IU/1 milliliter conventional release solution for injection (clinical drug),Hepatitis B immunoglobulin 110 IU/ml,HBIg 220,9542007,Product containing Hepatitis B surface antigen immunoglobulin (medicinal product),Hepatitis B immunoglobulin,HB Ig,J06BB04,hepatitis b immunoglobulin,HBIg HyperHEP B 110 IU/0.5 mL Grif,Marketed,Added,2023-06-23,,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100934
02520001,Health_Canada,02520001,,Hyperhep B,45871000087102,HyperHEP B 220 international units per milliliter solution for injection Grifols Therapeutics Inc. (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),Vials,1,hepatitis b immunoglobulin (human) 220 unit / mL solution for injection,Grifols Therapeutics Llc,SCT TBD 2,Product containing precisely Hepatitis B surface antigen immunoglobulin 220 IU/1 milliliter conventional release solution for injection (clinical drug),Hepatitis B surface antigen Immunoglobulin,HBSAIg,9542007,Product containing Hepatitis B surface antigen immunoglobulin (medicinal product),Hepatitis B immunoglobulin,HBIg,J06BB04,hepatitis b immunoglobulin,HBIg HyperHEP B 220 IU/mL Grif,Marketed,Added,2023-06-23,https://pdf.hres.ca/dpd_pm/00062962.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100923
02520133,Health_Canada,02520133,,Hyperhep B,45871000087102,HyperHEP B 220 international units per milliliter solution for injection Grifols Therapeutics Inc. (real clinical drug),solution,intramuscular,733020007,Syringe (unit of presentation),Prefilled syringe,1,hepatitis b immunoglobulin (human) 220 unit / mL solution for injection,Grifols Therapeutics Llc,SCT TBD 2,Product containing precisely Hepatitis B surface antigen immunoglobulin 220 IU/1 milliliter conventional release solution for injection (clinical drug),Hepatitis B surface antigen Immunoglobulin,HBSAIg,9542007,Product containing Hepatitis B surface antigen immunoglobulin (medicinal product),Hepatitis B immunoglobulin,HBIg,J06BB04,hepatitis b immunoglobulin,HBIg HyperHEP B 220 IU/mL Grif,Approved,Added,2024-10-16,https://health-products.canada.ca/dpd-bdpp/dispatch-repartition,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100935
02230738,Health_Canada,02230738,,Hyperhep B S/D,28411000087101,HyperHEP B S/D 220 international units per milliliter solution for injection Grifols Canada Limited (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),Also known as hepatitis b immune globulin human. 5ml vial,1,hepatitis b immunoglobulin (human) 220 unit / mL solution for injection,Grifols Therapeutics Llc,SCT TBD 2,Product containing precisely Hepatitis B surface antigen immunoglobulin 220 IU/1 milliliter conventional release solution for injection (clinical drug),Hepatitis B surface antigen Immunoglobulin,HBSAIg,9542007,Product containing Hepatitis B surface antigen immunoglobulin (medicinal product),Hepatitis B immunoglobulin,HBIg,J06BB04,hepatitis b immunoglobulin,HBIg HyperHEP B S/D 220 IU/mL Grif,Cancelled post market,Added,2023-06-23,https://pdf.hres.ca/dpd_pm/00036486.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50001
02379473,Health_Canada,02379473,,Hyperhep B S/D,28411000087101,HyperHEP B S/D 220 international units per milliliter solution for injection Grifols Canada Limited (real clinical drug),solution,intramuscular,733020007,Syringe (unit of presentation),Also known as hepatitis b immune globulin human. 1ml syringe,1,hepatitis b immunoglobulin (human) 220 unit / mL solution for injection,Grifols Therapeutics Llc,SCT TBD 2,Product containing precisely Hepatitis B surface antigen immunoglobulin 220 IU/1 milliliter conventional release solution for injection (clinical drug),Hepatitis B surface antigen Immunoglobulin,HBSAIg,9542007,Product containing Hepatitis B surface antigen immunoglobulin (medicinal product),Hepatitis B immunoglobulin,HBIg,J06BB04,hepatitis b immunoglobulin,HBIg HyperHEP B S/D 220 IU/mL Grif,Cancelled pre market,Modified,2022-11-24,https://pdf.hres.ca/dpd_pm/00036486.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86537
02486571,Health_Canada,02486571,,Hyperrab,31551000087108,HyperRAB 300 international units per milliliter solution for injection Grifols Therapeutics Inc. (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),,1,rabies immunoglobulin (human) 300 unit / mL solution for injection,Grifols Therapeutics Llc,31561000087106 ,Product containing precisely rabies human immune globulin 300 international unit/1 milliliter conventional release solution for injection (clinical drug),Rabies immunoglobulin high dose,Rabig HD,80834004,Product containing rabies human immune globulin (medicinal product),Rabies immunoglobulin,Rab Ig,J06BB05,rabies immunoglobulin,RabIg HYPERRAB Grif,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00060632.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97677
02230700,Health_Canada,02230700,,Hyperrab S/D,7961000087104,HYPERRAB S/D 150 international units per milliliter solution for injection Grifols Canada Limited (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),Also known as rabies immune globulin human,1,rabies immunoglobulin (human) 150 unit / mL solution for injection,Grifols Therapeutics Llc,789650005,Product containing precisely rabies human immune globulin 150 unit/1 milliliter conventional release solution for injection (clinical drug),Rabies immunoglobulin standard dose,Rabig SD,80834004,Product containing rabies human immune globulin (medicinal product),Rabies immunoglobulin,Rab Ig,J06BB05,rabies immunoglobulin,RabIg HYPERRAB S/D Grif,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00036488.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49960
02520087,Health_Canada,02520087,,Hypertet,33841000087107,HyperTET 250 antitoxin units per milliliter solution for injection Grifols Therapeutics Inc. (real clinical drug),solution,intramuscular,733020007,Syringe (unit of presentation),Pre-filled 1ml syringe,1,tetanus immunoglobulin (human) 250 unit / mL solution for injection,Grifols Therapeutics Llc,879842009,Product containing precisely human tetanus immunoglobulin 250 unit/1 milliliter conventional release solution for injection (clinical drug),Tetanus immunoglobulin 250,Tig 250,86337009,Product containing human tetanus immunoglobulin (medicinal product),Tetanus immunoglobulin,TIg,J06BB02,tetanus immunoglobulin,TIg HyperTET Grif,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00062963.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100930
02230697,Health_Canada,02230697,,Hypertet S/D,7981000087105,HYPERTET S/D 250 units per dose solution for injection Grifols Canada Limited (real clinical drug),solution,intramuscular,733020007,Syringe (unit of presentation),Also known as tetanus immune globuline human. single dose prefilled syringe,1,tetanus immunoglobulin (human) 250 unit / dose solution for injection,Grifols Therapeutics Llc,879842009,Product containing precisely human tetanus immunoglobulin 250 unit/1 milliliter conventional release solution for injection (clinical drug),Tetanus immunoglobulin 250,Tig 250,86337009,Product containing human tetanus immunoglobulin (medicinal product),Tetanus immunoglobulin,TIg,J06BB02,tetanus immunoglobulin,TIg HYPERTET S/D Grif,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00036491.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49957
02379619,Health_Canada,02379619,,Hypertet S/D,7981000087105,HYPERTET S/D 250 units per dose solution for injection Grifols Canada Limited (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),Also known as tetanus immune globulin (human). single dose vial,1,tetanus immunoglobulin (human) 250 unit / dose solution for injection,Grifols Therapeutics Llc,879842009,Product containing precisely human tetanus immunoglobulin 250 unit/1 milliliter conventional release solution for injection (clinical drug),Tetanus immunoglobulin 250,Tig 250,86337009,Product containing human tetanus immunoglobulin (medicinal product),Tetanus immunoglobulin,TIg,J06BB02,tetanus immunoglobulin,TIg HYPERTET S/D Grif,Cancelled pre market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00036491.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86549
02230647,Health_Canada,02230647,,Immune Serum Globulin (Human),19471000087105,IMMUNE SERUM GLOBULIN (HUMAN) 15 to 18 percent solution for injection Grifols Therapeutics Inc. (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),,1,immunoglobulin (human) 18 % solution for injection,Grifols Therapeutics Llc,780035005,Product containing only normal human immunoglobulin in parenteral dose form (medicinal product form),Normal Human Immunoglobulin,Ig normal,333711001,Product containing human immunoglobulin (medicinal product),Immune globulin,Ig,J06BA01,"immunoglobulins, normal human, for extravasc. adm",Ig IMMUNE SERUM GLOBULIN (HUMAN) Grif,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00027354.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49876
02237328,Health_Canada,02237328,,Imogam Rabies Pasteurized,7971000087108,IMOGAM 150 international units per milliliter solution for injection Sanofi Pasteur SA (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),Also known as rabies immune globulin human,1,rabies immunoglobulin (human) 150 unit / mL solution for injection,Sanofi Pasteur Limited,789650005,Product containing precisely rabies human immune globulin 150 unit/1 milliliter conventional release solution for injection (clinical drug),Rabies immunoglobulin standard dose,Rabig SD,80834004,Product containing rabies human immune globulin (medicinal product),Rabies immunoglobulin,Rab Ig,J06BB05,rabies immunoglobulin,RabIg IMOGAM SP,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00032930.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60651
01959042,Health_Canada,01959042,66124773,Imovax Polio,7361000087100,IMOVAX Polio 80 units per 0.5 milliliter solution for injection Sanofi Pasteur Limited (real clinical drug),solution,subcutaneous,733020007,Syringe (unit of presentation),,3,poliovirus type 1 mahoney (inactivated) 29 unit / 0.5 mL + poliovirus type 2 mef1 (inactivated) 7 unit / 0.5 mL + poliovirus type 3 saukett (inactivated) 26 unit / 0.5 mL solution for injection,Sanofi Pasteur Limited,56841000087103,Vaccine product containing only standard dose inactivated whole Human poliovirus antigen (medicinal product),Inactivated whole poliovirus antigen SD,IwPV SD,871739009,Vaccine product containing only Human poliovirus antigen (medicinal product),Polio,IPV,J07BF03,"poliomyelitis, trivalent, inactivated, whole virus",IPV Imovax Polio SP,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00012948.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=44019
01908286,Health_Canada,01908286,,Imovax Rabies Rabies Vaccine Inactivated (Dco),7381000087106,Imovax Rabies 2.5 international units per milliliter powder for solution for injection Sanofi Pasteur Limited (real clinical drug),powder for suspension,intramuscular,733026001,Vial (unit of presentation),,1,inactivated rabies virus (pm/wi38 1503-3m) 2.5 unit / vial powder for suspension for injection,Sanofi Pasteur Limited,1131000221109,Vaccine product containing only inactivated whole Rabies lyssavirus antigen (medicinal product),Rabies inactivated whole virus,RAB-IV,871726005,Vaccine product containing only Rabies lyssavirus antigen (medicinal product),Rabies,Rab,J07BG01,"rabies, inactivated, whole virus",Rab Imovax Rabies SP,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00060488.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=46832
02416638,Health_Canada,02416638,66128369,Imvamune,26571000087105,IMVAMUNE 50000000 units per 0.5 milliliter suspension for injection Bavarian Nordic AS (real clinical drug),suspension,subcutaneous,733026001,Vial (unit of presentation),,1,,Bavarian Nordic AS,1269346004,Vaccine product containing only live attenuated Vaccinia virus antigen (medicinal product),Vaccinia attenuated virus,VACV-LA,871727001,Vaccine product containing only Vaccinia virus antigen (medicinal product),Small pox,Sma,J07BX01,smallpox and monkeypox vaccines,SMV IMVAMUNE BN,Restricted,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00063755.PDF,
02253852,Health_Canada,02253852,66124776,Infanrix-Hexa,7451000087107,INFANRIX hexa suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,419179001,Kit - unit of product usage (qualifier value),,11,diphtheria toxoid 25 LF / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 25 mcg / 0.5 mL + haemophilus influenzae type b-prp 10 mcg / 0.5 mL + hepatitis b surface antigen (recombinant) 10 mcg / 0.5 mL + pertactin (b. pertussis virulence factor) 8 mcg / 0.5 mL + pertussis toxoid 25 mcg / 0.5 mL + poliovirus type 1 mahoney (inactivated) 40 unit / 0.5 mL + poliovirus type 2 mef1 (inactivated) 8 unit / 0.5 mL + poliovirus type 3 saukett (inactivated) 32 unit / 0.5 mL + tetanus toxoid 10 LF / 0.5 mL + tetanus toxoid adsorbed 40 mcg / 0.5 mL suspension for injection,Glaxosmithkline Inc,7731000087108,Pediatric vaccine product containing only diphtheria standard dose + tetanus + acellular pertussis standard dose + hepatitis b + inactivated human poliovirus + Haemophilus influenzae type b antigens (medicinal product),Diphtheria + Tetanus + Pertussis + Hepatitis B + Polio + Hib pediatric,DTaP-HB-IPV-Hib ped,1162637003,Vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and Hepatitis B virus and inactivated Human poliovirus antigens (medicinal product),Diphtheria + Tetanus + aPertussis + Hepatitis B + Polio + Hib pediatric,DTaP-HB-IPV-Hib,J07CA02,diphtheria-pertussis-poliomyelitis-tetanus,DTaP-HB-IPV-Hib INFANRIX hexa GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00062366.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73878
02241284,Health_Canada,02241284,,Infanrix-Ipv,7461000087105,INFANRIX-IPV suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Pre-filled syringes,8,diphtheria toxoid 30 unit / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 25 mcg / 0.5 mL + inactivated poliovirus type i 40 unit / 0.5 mL + inactivated poliovirus type ii 8 unit / 0.5 mL + inactivated poliovirus type iii 32 unit / 0.5 mL + pertactin (b. pertussis virulence factor) 8 mcg / 0.5 mL + pertussis toxoid 25 mcg / 0.5 mL + tetanus toxoid 40 unit / 0.5 mL suspension for injection,Glaxosmithkline Inc,7881000087101,Pediatric vaccine product containing diphtheria standard dose + tetanus + acellular pertussis standard dose + inactivated human poliovirus antigens (medicinal product),Diphtheria + Tetanus + Pertussis + Polio pediatric,DTaP-IPV ped,871878002,Vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (medicinal product),Diphtheria + Tetanus + aPertussis + Polio,DTaP-IPV,J07CA02,diphtheria-pertussis-poliomyelitis-tetanus,DTaP-IPV INFANRIX-IPV GSK,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00026837.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64893
02257122,Health_Canada,02257122,,Infanrix-Ipv/Hib,7501000087105,INFANRIX-IPV/Hib suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,419179001,Kit - unit of product usage (qualifier value),,9,diphtheria toxoid 30 unit / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 25 mcg / 0.5 mL + haemophilus influenzae type b-prp and tetanus toxoid conjugate (prp-t) 10 mcg / 0.5 mL + inactivated poliovirus type i 40 unit / 0.5 mL + inactivated poliovirus type ii 8 unit / 0.5 mL + inactivated poliovirus type iii 32 unit / 0.5 mL + pertactin (b. pertussis virulence factor) 8 mcg / 0.5 mL + pertussis toxoid 25 mcg / 0.5 mL + tetanus toxoid 40 unit / 0.5 mL suspension for injection,Glaxosmithkline Inc,7931000087106,Pediatric vaccine product containing only diphtheria standard dose + tetanus + acellular pertussis standard dose + inactivated human poliovirus + Haemophilus influenzae type b antigens (medicinal product),Diphtheria + Tetanus + Pertussis + Polio + Hib pediatric,DTaP-IPV-Hib ped,871887006,Vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and Human poliovirus antigens (medicinal product),DTaP-IPV-Hib,DTaP-IPV-Hib,J07CA06,dipht-hemoph influen b-pertuss-polio-tetanus,DTaP-IPV-Hib INFANRIX-IPV/Hib GSK,Dormant,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00039504.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74234
28591000087108,SNOMED-CT,,66127296,Influsplit Tetra,28591000087108,INFLUSPLIT TETRA 15 micrograms per 0.5 milliliter suspension for injection GlaxoSmithKline Biologicals (real clinical drug),Suspension,,733020007,Syringe (unit of presentation),,4,,GlaxoSmithKline Biologicals,19401000087100,Vaccine product containing only Influenza virus 4 strains antigens (medicinal product),Influenza quadrivalent,inf quad,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf INFLUSPLIT TETRA GSK,International,Added,2022-03-31,https://www.tbdhu.com/sites/default/files/files/resource/2020-12/GSK%20Influsplit%20Tetra%202020-2021%20PI%20Translated%20English.pdf,
02269562,Health_Canada,02269562,,Influvac,22681000087109,INFLUVAC 15 micrograms per 0.5 milliliter suspension for injection BGP Pharma ULC (real clinical drug),suspension,intramuscular OR subcutaneous,733020007,Syringe (unit of presentation),Pre-filled syringes. 1 or 10 per pack. preservative free.,3,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b 15 mcg / 0.5 mL suspension for injection,Bgp Pharma Ulc,28191000087104,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B unadjuvanted standard dose,Inf H1N1+H3N2+B unadj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB01,"influenza, inactivated, whole virus",Inf INFLUVAC BGP,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00045022.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75489
02484854,Health_Canada,02484854,66128295,Influvac Tetra,28611000087103,INFLUVAC TETRA 15 micrograms per 0.5 milliliter suspension for injection BGP Pharma ULC (real clinical drug),suspension,subcutaneous OR intramuscular,733020007,Syringe (unit of presentation),,4,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b (victoria) 15 mcg / 0.5 mL + haemagglutinin-strain b (yamagata) 15 mcg / 0.5 mL suspension for injection,Bgp Pharma Ulc,28181000087101,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus Victoria and Yamagata lineage standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B+YV unadjuvanted standard dose,Inf H1N1+H3N2+B+YV SD,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf INFLUVAC TETRA BGP,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00063780.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97512
02348764,Health_Canada,02348764,,Intanza,7611000087106,Intanza 15 micrograms per 0.1 milliliter suspension for injection Sanofi Pasteur SA (real clinical drug),suspension,intradermal,733020007,Syringe (unit of presentation),Prefilled syringe. for persons 60 yrs and over,3,haemagglutinin-strain a (h1n1) 15 mcg / 0.1 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.1 mL + haemagglutinin-strain b 15 mcg / 0.1 mL intradermal suspension,Sanofi Pasteur Limited,28191000087104,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B unadjuvanted standard dose,Inf H1N1+H3N2+B unadj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf INTANZA 15 micrograms SP,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00022265.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83410
02348756,Health_Canada,02348756,,Intanza,7601000087109,Intanza 9 micrograms per 0.1 milliliter suspension for injection Sanofi Pasteur SA (real clinical drug),suspension,intradermal,733020007,Syringe (unit of presentation),Prefilled syringe. for persons 18 to 59 yrs old,3,haemagglutinin-strain a (h1n1) 9 mcg / 0.1 mL + haemagglutinin-strain a (h3n2) 9 mcg / 0.1 mL + haemagglutinin-strain b 9 mcg / 0.1 mL intradermal suspension,Sanofi Pasteur Limited,28191000087104,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B unadjuvanted standard dose,Inf H1N1+H3N2+B unadj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf INTANZA 9 micrograms SP,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00022265.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83409
02548984,Health_Canada,02548984,,Ixchiq,61241000087101,IXCHIQ not less than 3.0 log10 TCID50 per 0.5 milliliter powder for solution for injection Valneva Austria GmbH (real clinical drug),powder for solution,intramuscular,733026001,Vial (unit of presentation),,1,chikungunya virus live-attenuated 3 Log10 TCID50 / 0.5 mL powder for solution for injection,Valneva Austria Gmbh,1345036005,Vaccine product containing only live attenuated Chikungunya virus antigen (medicinal product),Chikungunga virus live attenuated oral,Chik-LA,1345202008,Vaccine product containing only Chikungunya virus antigen (medicinal product),Chikungunga antigen,Chik,J07BX07,chikungunya vaccines,Chik IXCHIQ VAL,Marketed,Added,2024-09-19,https://pdf.hres.ca/dpd_pm/00076049.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103787
02333279,Health_Canada,02333279,,Ixiaro,21771000087109,IXIARO 6 micrograms per 0.5 milliliter suspension for injection Valneva Austria GmbH (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),,1,inact.japanese encephal virus(attenuat. strain sa14-14-2 produced in vero cells) 6 mcg / 0.5 mL suspension for injection,Valneva Austria Gmbh,871725009,Vaccine product containing only inactivated whole Japanese encephalitis virus antigen (medicinal product),Japanese encephalitis Inactivated,JE-IA,871724008,Vaccine product containing only Japanese encephalitis virus antigen (medicinal product),Japanese encephalitis,JE,J07BA02,"encephalitis, japanese, inactivated, whole virus",JE IXIARO VAL,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00044740.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81890
02513153,Health_Canada,02513153,,Jcovden,28951000087107,JCOVDEN non-replicant vector 0.5 milliliter suspension for injection Janssen Inc. (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Vial contains 5 doses of 0.5ml,1,ad26.cov2.s [recombinant] 50000000000 vaginal pessary / 0.5 mL suspension for injection,Janssen Inc,29061000087103,Vaccine product containing only recombinant non-replicating viral vector encoding severe acute respiratory syndrome coronavirus 2 spike protein (medicinal product),COVID-19 non-replicating vector,COVID-19 NRV,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN02,"covid-19, viral vector, non-replicating",COVID-19 JCOVDEN Jan,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00067954.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100239
02048744,Health_Canada,02048744,,Je-Vax 1 Dose,9821000087106,JE-VAX 50 nanograms per milliliter suspension for injection The Research Foundation for Microbial Diseases of Osaka University (real clinical drug),powder for suspension AND kit,subcutaneous,419179001,Kit - unit of product usage (qualifier value),,2,"japanese encephalitis virus vaccine, inactivated 1 unit / vial with water 1.3 ml / vial kit (powder for suspension) for injection",(Biken) The Res.Found.For Microb.Dis.Osaka University,871725009,Vaccine product containing only inactivated whole Japanese encephalitis virus antigen (medicinal product),Japanese encephalitis Inactivated,JE-IA,871724008,Vaccine product containing only Japanese encephalitis virus antigen (medicinal product),Japanese encephalitis,JE,J07BA02,"encephalitis, japanese, inactivated, whole virus",JE JE-VAX Bik,Cancelled post market,Added,2022-03-31,,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16063
02482436,Health_Canada,02482436,,Kamrab,28361000087109,KamRAB 150 international units per milliliter solution for injection Kamada Ltd (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),2 ml vial,1,rabies immunoglobulin (human) 150 unit / mL solution for injection,Kamada Ltd,789650005,Product containing precisely rabies human immune globulin 150 unit/1 milliliter conventional release solution for injection (clinical drug),Rabies immunoglobulin standard dose,Rabig SD,80834004,Product containing rabies human immune globulin (medicinal product),Rabies immunoglobulin,Rab Ig,J06BB05,rabies immunoglobulin,RabIg KamRAB KAM,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00048173.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97288
02482509,Health_Canada,02482509,,Kamrab,28361000087109,KamRAB 150 international units per milliliter solution for injection Kamada Ltd (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),10 ml vial,1,rabies immunoglobulin (human) 150 unit / mL solution for injection,Kamada Ltd,789650005,Product containing precisely rabies human immune globulin 150 unit/1 milliliter conventional release solution for injection (clinical drug),Rabies immunoglobulin standard dose,Rabig SD,80834004,Product containing rabies human immune globulin (medicinal product),Rabies immunoglobulin,Rab Ig,J06BB05,rabies immunoglobulin,RabIg KamRAB KAM,Approved,Added,2023-06-23,https://pdf.hres.ca/dpd_pm/00048173.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97295
02556332,Health_Canada,02556332,,Kavigale,SCT TBD 45,KAVIGALE 150 milligrams per 1 milliliter solution for injection AstaZenica Canada Inc. (real clinical drug),solution,intravenous OR intramuscular,733026001,Vial (unit of presentation),Single use vial,1,sipavibart 150 mg / mL solution for injection,Astrazeneca Canada Inc,SCT TBD 46,Product containing precisely Sipavibart 150 milligram/1 milliliter conventional release solution for injection (clinical drug),COVID-19 sipavibart recombinant IgG1 monoclonal antibody,COVID-19 sipavibart,SCT TBD 22,Product containing only COVID-19 monoclonal antibody (medicinal product),SARS-CoV-2 monoclonal antibody,Covid-19 mAb,J06BD09,sipavibart,COVID-19 KAVIGALE 150 mg / 1 ml AZC,Approved,Added,2025-08-23,https://pdf.hres.ca/dpd_pm/00080248.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104503
33431000087104,SNOMED-CT,,,KConvac,33431000087104,KCONVAC COVID-19 whole inactivated virus vaccine (real medicinal product),,,,,,,,Minhai Biotechnology Co.,1157024006,Vaccine product containing only inactivated whole severe acute respiratory syndrome coronavirus 2 antigen (medicinal product),COVID-19 whole inactivated virus,COVID-19 WIV,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN03,"covid-19, inactivated virus",COVID-19 KCONVAC,International,Added,2022-03-31,https://covid19.trackvaccines.org/vaccines/47/,
22691000087106,SNOMED-CT,,,Kinrix,22691000087106,KINRIX suspension for injection GlaxoSmithKline Biologicals (real clinical drug),,,,,,,,GlaxoSmithKline Biologicals,7881000087101,Pediatric vaccine product containing diphtheria standard dose + tetanus + acellular pertussis standard dose + inactivated human poliovirus antigens (medicinal product),Diphtheria + Tetanus + Pertussis + Polio pediatric,DTaP-IPV ped,871878002,Vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (medicinal product),Diphtheria + Tetanus + aPertussis + Polio,DTaP-IPV,J07CA02,diphtheria-pertussis-poliomyelitis-tetanus,DTaP-IPV KINRIX GSK,International,Added,2022-03-31,https://www.fda.gov/media/80128/download,
02235721,Health_Canada,02235721,,Liquid Pedvaxhib,7051000087101,Liquid PedvaxHIB suspension for injection Merck Canada Inc. (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),,2,haemophilus influenzae type b-prp 7.5 mcg / 0.5 mL + neisseria meningitidis outer membrane protein complex 125 mcg / 0.5 mL suspension for injection,Merck Canada Inc,2041000221105,Vaccine product containing only Haemophilus influenzae type b capsular polysaccharide antigen conjugated (medicinal product),Conjugated Haemophilus influenza type b,Hib-C,871764007,Vaccine product containing only Haemophilus influenzae type B antigen (medicinal product),Haemophilus influenzae type b,Hib,J07AG01,"hemophilus influenzae b, purified antig. conjugated",Hib Liquid PedvaxHIB MC,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00013616.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=59709
33441000087105,SNOMED-CT,,,Medigen-Dynavax-NIAID,33441000087105,Medgen-Dynavax-NIAID COVID-19 recombinant spike protein vaccine (real medicinal product),,,,,,,,Medigen,1162643001,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN04,covid-19 protein subunit,COVID-19 Medigen-Dynavax-NIAID,International,Added,2022-03-31,https://covid19.trackvaccines.org/vaccines/24/,
02279924,Health_Canada,02279924,66128072,Menactra,7131000087109,Menactra solution for injection Sanofi Pasteur Limited (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),,4,"meningococcal polysaccharide-diphtheria toxoid conjugate, group a 4 mcg / 0.5 mL + meningococcal polysaccharide-diphtheria toxoid conjugate, group c 4 mcg / 0.5 mL + meningococcal polysaccharide-diphtheria toxoid conjugate, group w 135 4 mcg / 0.5 mL + meningococcal polysaccharide-diphtheria toxoid conjugate, group y 4 mcg / 0.5 mL solution for injection",Sanofi Pasteur Limited,7121000087107,Vaccine product containing only meningococcal groups A + C + Y + W conjugate antigens (medicinal product),Meningococcal A+C+Y+W-135 conjugated,Men-C-ACYW-135,921000221108,Vaccine product containing only Neisseria meningitidis antigen (medicinal product),Meningococcal,Men,J07AH08,"meningococcus, a, c, y, w-135, tetraval. purified polysacc. antigen conjugated",Men-C-ACYW-135 Menactra SP,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00042668.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76550
20851000087103,SNOMED-CT,,,Menhibrix,20851000087103,MENHIBRIX solution for injection GlaxoSmithKline Biologicals (real clinical drug),,,,,,,,GlaxoSmithKline Biologicals,20681000087105,Vaccine product containing only meningococcal groups C + Y conjugated + Haemophilus influenzae type b antigens (medicinal product),Meningococcal C + Y + Hib conjugated,Men-C-CY-Hib,921000221108,Vaccine product containing only Neisseria meningitidis antigen (medicinal product),Meningococcal,Men,J07AG54,"haemophilus influenza b, combinations with meningococcus c,y, conjugated",Men-C-CY-Hib MENHIBRIX GSK,International,Added,2022-03-31,https://www.fda.gov/media/83688/download,
02248649,Health_Canada,02248649,66124832,Meningitec,26581000087107,MENINGITEC 10 micrograms per 0.5 milliliter suspension for injection Nuron Biotech B.V. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),10 pre-filled syringes,2,corynebacterium diphtheriae crm-197 protein 15 mcg / 0.5 mL + meningococcal group c oligosaccharide 10 mcg / 0.5 mL suspension for injection,Nuron Biotech B.V.,27511000087101,Vaccine product containing only Neisseria meningitidis serogroup C conjugated antigen (medicinal product),Meningococcal C conjugated antigen,Men-C-C,921000221108,Vaccine product containing only Neisseria meningitidis antigen (medicinal product),Meningococcal,Men,J07AH07,"meningococcus c, purified polysaccharides antigen conjugated",Men-C-C MENINGITEC NB,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00022676.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73006
02440709,Health_Canada,02440709,66128114,Menjugate Liquid,21691000087104,MENJUGATE Liquid 10 micrograms suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),0.5 ml single dose prefilled syringes,2,corynebacterium diphtheriae crm-197 protein 25 mcg / 0.5 mL + meningococcal group c oligosaccharide 10 mcg / 0.5 mL suspension for injection,Glaxosmithkline Inc,27511000087101,Vaccine product containing only Neisseria meningitidis serogroup C conjugated antigen (medicinal product),Meningococcal C conjugated antigen,Men-C-C,921000221108,Vaccine product containing only Neisseria meningitidis antigen (medicinal product),Meningococcal,Men,J07AH,meningococcal vaccines,Men-C-C MENJUGATE Liquid GSK,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00052073.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92507
01959018,Health_Canada,01959018,,Menomune-A/C/Y/W-135,7111000087104,MENOMUNE - A/C/Y/W-135 powder and diluent for solution for injection Sanofi Pasteur Inc. (real clinical drug),powder for solution AND kit,subcutaneous,733026001,Vial (unit of presentation),,4,meningococcal polysaccharide antigen group a 50 mcg / 0.5 mL with meningococcal polysaccharide antigen group c 50 mcg / 0.5 mL with meningococcal polysaccharide antigen group w-135 50 mcg / 0.5 mL with meningococcal polysaccharide antigen group y 50 mcg / 0.5 mL kit (powder for solution) for injection,Sanofi Pasteur Limited,7101000087101,Vaccine product containing only meningococcal groups A + C + Y + W-135 capsular polysaccharide unconjugated antigens (medicinal product),Meningococcal A+C+Y+W-135 unconjugated,Men-P-ACYW-135,921000221108,Vaccine product containing only Neisseria meningitidis antigen (medicinal product),Meningococcal,Men,J07AH04,"meningococcus, a, c, y, w-135, tetraval. purified polysacc. antigen",Men-P-ACYW-135 MENOMUNE-A/C/Y/W-135 SP,Cancelled post market,Added,2024-04-03,https://pdf.hres.ca/dpd_pm/00023389.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=46485
02507161,Health_Canada,02507161,,Menquadfi,56051000087108,MenQuadfi solution for injection Sanofi Pasteur Limited (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),Single dose vial,5,meningococcal group a polysaccharide-tetanus toxoid conjugate 10 mcg / 0.5 mL + meningococcal group c polysaccharide-tetanus toxoid conjugate 10 mcg / 0.5 mL + meningococcal group w polysaccharide-tetanus toxoid conjugate 10 mcg / 0.5 mL + meningococcal group y polysaccharide-tetanus toxoid conjugate 10 mcg / 0.5 mL + tetanus toxoid 55 mcg / 0.5 mL solution for injection,Sanofi Pasteur Limited,7121000087107,Vaccine product containing only meningococcal groups A + C + Y + W conjugate antigens (medicinal product),Meningococcal A+C+Y+W-135 conjugated,Men-C-ACYW-135,921000221108,Vaccine product containing only Neisseria meningitidis antigen (medicinal product),Meningococcal,Men,J07AH08,"meningococcus, a, c, y, w-135, tetraval. purified polysacc. antigen conjugated",Men-C-ACYW MenQuadfi SP,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00058534.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99657
02563029,Health_Canada,02563029,66128071,Menveo,SCT TBD 50,Menveo solution for injection GlaxoSmithKline Inc. (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),Single-use vial,4,,Glaxosmithkline Inc,7121000087107,Vaccine product containing only meningococcal groups A + C + Y + W conjugate antigens (medicinal product),Meningococcal A+C+Y+W-135 conjugated,Men-C-ACYW-135,921000221108,Vaccine product containing only Neisseria meningitidis antigen (medicinal product),Meningococcal,Men,J07AH08,"meningococcus, a, c, y, w-135, tetraval. purified polysacc. antigen conjugated",Men-C-ACYW-135 Menveo GSK,Approved,Added,2026-01-15,https://pdf.hres.ca/dpd_pm/00082773.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106585
02347393,Health_Canada,02347393,66128071,Menveo,21681000087101,Menveo powder and solution for injection GlaxoSmithKline Inc. (real clinical drug),solution AND powder for solution,intramuscular,733026001,Vial (unit of presentation),1 vial lyoph. men. a conjugate & 1 vial  sol. men. cwy conjugate,5,corynebacterium diphtheriae crm-197 protein 47 mcg / 0.5 mL + meningococcal group a oligosaccharide 10 mcg / 0.5 mL + meningococcal group c oligosaccharide 5 mcg / 0.5 mL + meningococcal group w-135 oligosaccharide 5 mcg / 0.5 mL + meningococcal group y oligosaccharide 5 mcg / 0.5 mL powder for solution or solution for injection,Glaxosmithkline Inc,7121000087107,Vaccine product containing only meningococcal groups A + C + Y + W conjugate antigens (medicinal product),Meningococcal A+C+Y+W-135 conjugated,Men-C-ACYW-135,921000221108,Vaccine product containing only Neisseria meningitidis antigen (medicinal product),Meningococcal,Men,J07AH08,"meningococcus, a, c, y, w-135, tetraval. purified polysacc. antigen conjugated",Men-C-ACYW-135 Menveo GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00082773.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83276
00466085,Health_Canada,00466085,66124781,M-M-R Ii,7161000087102,M-M-R II powder and diluent for solution for injection Merck Canada Inc. (real clinical drug),powder for solution,intramuscular OR subcutaneous,733026001,Vial (unit of presentation),,3,measles virus live attenuated (edmonston strain) 1000 CCID50 / 0.5 mL + mumps virus live attenuated (jeryl lynn strain) 5000 CCID50 / 0.5 mL + rubella virus live attenuated (wistar ra27/3 strain) 1000 CCID50 / 0.5 mL powder for solution for injection,Merck Canada Inc,2241000221103,Vaccine product containing only live attenuated Measles morbillivirus and Mumps orthorubulavirus and Rubella virus antigens (medicinal product),Measles + Mumps + Rubella live attenuated,MMR live,871831003,Vaccine product containing only Measles morbillivirus and Mumps orthorubulavirus and Rubella virus antigens (medicinal product),Measles + Mumps + Rubella,MMR,J07BD52,"measles, combin. with mumps and rubella, live attenuated",MMR M-M-R II Merck,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00060438.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3569
02561433,Health_Canada,02561433,,Mnexspike LP.8.1,379371000087107,mNEXSPIKE messenger ribonucleic acid 10 micrograms per 0.2 milliliter dispersion for injection Moderna Biopharma Canada Corporation (real clinical drug),dispersion,intramuscular,733020007,Syringe (unit of presentation),"Single-dose, pre-filled syringe",1,sars-cov-2 s-protein ntd-rbd mrna 10 mcg / 0.2 mL dispersion for injection,Moderna Biopharma Canada Corporation,1162643001,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 mNEXSPIKE LP.8.1 50 mcg/mL mRNA Mod,Approved,Added,2025-11-15,https://pdf.hres.ca/dpd_pm/00081916.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106440
45861000087106,SNOMED-CT,,,"Mosquirix (RTS,S)",45861000087106,Vaccine product containing Plasmodium falciparum antigen (medicinal product),,,,,,,,GalaxoSmithKline Biologicals,SCT TBD 29,"Vaccine product containing only malaria RTS,S/AS01 recombinant circumsporozoite protein antigen",Malaria recombinant circumsporate protein antigen,Mal recomb,SCT TBD 39,Product containing only malaria antigen,Malaria antigen,Mal,J07XA01,malaria vaccines,Malaria MOSQUIRIX,International,Added,2024-04-03,https://www.nitag-resource.org/sites/default/files/2022-05/mosquirix-medicine-overview_en.pdf,
02552914,Health_Canada,02552914,,Mresvia,61761000087105,mRESVIA 50 micrograms per 0.5 milliliter dispersion for injection Moderna Biopharma Canada Corporation (real clinical drug),dispersion,intramuscular,733020007,Syringe (unit of presentation),Single use prefilled syringe,1,rsv f-protein mrna 50 mcg / 0.5 mL dispersion for injection,Moderna Biopharma Canada Corporation,61771000087101,Vaccine product containing only Human orthopneumovirus messenger ribonucleic acid (medicinal product),Respiratory syncytial virus recombinant,RSV recomb,51311000087100,Vaccine product containing only Human orthopneumovirus antigen (medicinal product),RSV antigen,RSV mRNA,J07BX05,respiratory syncytial virus vaccine,RSV mRESVIA mRNA Mod,Approved,Added,2024-12-11,https://pdf.hres.ca/dpd_pm/00077692.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104187
02245057,Health_Canada,02245057,66124782,Neisvac-C,21891000087103,NeisVac-C 10 micrograms per 0.5 milliliter suspension for injection Pfizer Canada ULC (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),,2,meningococcal polysaccharide vaccine grp c 10 mcg / 0.5 mL + tetanus toxoid 20 mcg / 0.5 mL suspension for injection,Pfizer Canada Ulc,951000221102,Vaccine product containing only Neisseria meningitidis serogroup C capsular polysaccharide conjugated antigen (medicinal product),Meningococcal C conjugated polysaccharide,Men-C-C,921000221108,Vaccine product containing only Neisseria meningitidis antigen (medicinal product),Meningococcal,Men,J07AH07,"meningococcus c, purified polysaccharides antigen conjugated",Men-C-C NeisVac-C Pfiz,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00063329.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69061
02402904,Health_Canada,02402904,66128152,Nimenrix,21781000087106,NIMENRIX powder and diluent for solution for injection Pfizer Canada ULC (real clinical drug),powder for solution AND kit,intramuscular,733026001,Vial (unit of presentation),Single-dose vial with diluent (0.5ml in a prefilled-syringe). 1 & 10 kits,5,meningococcal polysaccharide antigen group a 5 mcg / 0.5 mL with meningococcal polysaccharide antigen group c 5 mcg / 0.5 mL with meningococcal polysaccharide antigen group w-135 5 mcg / 0.5 mL with meningococcal polysaccharide antigen group y 5 mcg / 0.5 mL with tetanus toxoid 44 mcg / 0.5 mL kit (powder for solution) for injection,Pfizer Canada Ulc,7121000087107,Vaccine product containing only meningococcal groups A + C + Y + W conjugate antigens (medicinal product),Meningococcal A+C+Y+W-135 conjugated,Men-C-ACYW-135,921000221108,Vaccine product containing only Neisseria meningitidis antigen (medicinal product),Meningococcal,Men,J07AH04,"meningococcus, a, c, y, w-135, tetraval. purified polysacc. antigen",Men-C-ACYW-135 NIMENRIX Pfiz,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00062618.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88773
02525364,Health_Canada,02525364,,Nuvaxovid,29171000087106,NUVAXOVID (original strain) recombinant spike protein 5 micrograms per 0.5 milliliter suspension for injection Novavax Inc. (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),2.5 ml vial containing 5 doses and 5ml vial containing 10 doses,1,sars-cov-2 recombinant spike protein 5 mcg / 0.5 mL suspension for injection,Novavax Inc.,1162643001,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN04,"covid-19, protein subunit",COVID-19 NUVAXOVID (original strain) Nova,Cancelled post market,Added,2022-11-24,https://pdf.hres.ca/dpd_pm/00065155.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101438
02543656,Health_Canada,02543656,,Nuvaxovid,60851000087107,NUVAXOVID recombinant spike protein 5 micrograms per 0.5 milliliter suspension for injection Novavax Inc. (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Multidose vial (vial contains 5 doses of 0.5ml),1,sars-cov-2 recombinant spike protein 5 mcg / 0.5 mL suspension for injection,Novavax Inc.,1162643001,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN04,"covid-19, protein subunit",COVID-19 NUVAXOVID Omicron JN.1 Nova,Dormant,Modified,2024-12-14,https://pdf.hres.ca/dpd_pm/00077115.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103210
02558998,Health_Canada,02558998,,Nuvaxovid JN.1,60851000087107,NUVAXOVID recombinant spike protein 5 micrograms per 0.5 milliliter suspension for injection Novavax Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Single-dose pre-filled syringe,1,sars-cov-2 recombinant spike protein 5 mcg / 0.5 mL suspension for injection,Novavax Inc.,1162643001,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN04,"covid-19, protein subunit",COVID-19 NUVAXOVID JN.1 Nova,Approved,Added,2025-08-23,https://pdf.hres.ca/dpd_pm/00080962.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106219
02542714,Health_Canada,02542714,,Panenza,21871000087102,Influenza A (H1N1) 2009 Pandemic Monovalent Vaccine (Without Adjuvant) 15 micrograms per 0.5 milliliter suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,,,Multidose vial,1,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL suspension for injection,Sanofi Pasteur Limited,805595741000087102,Unadjuvanted vaccine product containing only non-live Influenza A virus subtype H1N1 antigen in parenteral dose form (medicinal product form),Influenza A monovalent H1N1 unadjuvanted,Inf H1N1 unadj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf PANENZA SP,Approved,Added,2024-12-11,https://pdf.hres.ca/dpd_pm/00073058.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103125
02243167,Health_Canada,02243167,66124783,Pediacel,7521000087104,PEDIACEL suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),,11,diphtheria toxoid 15 LF / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 20 mcg / 0.5 mL + fimbriae (b. pertussis antigen) 5 mcg / 0.5 mL + haemophilus influenzae type b-prp 10 mcg / 0.5 mL + inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney 29 unit / 0.5 mL + inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1 7 unit / 0.5 mL + inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett 26 unit / 0.5 mL + pertactin (b. pertussis virulence factor) 3 mcg / 0.5 mL + pertussis toxoid 20 mcg / 0.5 mL + tetanus protein 30 mcg / 0.5 mL + tetanus toxoid 5 LF / 0.5 mL suspension for injection,Sanofi Pasteur Limited,7931000087106,Pediatric vaccine product containing only diphtheria standard dose + tetanus + acellular pertussis standard dose + inactivated human poliovirus + Haemophilus influenzae type b antigens (medicinal product),Diphtheria + Tetanus + Pertussis + Polio + Hib pediatric,DTaP-IPV-Hib ped,871887006,Vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and Human poliovirus antigens (medicinal product),DTaP-IPV-Hib,DTaP-IPV-Hib,J07CA06,dipht-hemoph influen b-pertuss-polio-tetanus,DTaP-IPV-Hib PEDIACEL SP,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00015723.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67042
20841000087101,SNOMED-CT,,,Pediarix,20841000087101,PEDIARIX suspension for injection GlaxoSmithKline Inc. (real clinical drug),,,,,,,,GlaxoSmithKline Inc.,20641000087100,Pediatric vaccine product containing only diphtheria standard dose + tetanus + acellular pertussis standard dose + hepatitis b + inactivated human poliovirus antigens (medicinal product),Diphtheria + Tetanus + Pertussis + Hepatitis B + Polio pediatric,DTaP-HB-IPV ped,871891001,Vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Hepatitis B virus and inactivated whole Human poliovirus antigens (medicinal product),Diphtheria + Tetanus + aPertussis + Hepatitis B + Polio,DTaP-HB-IPV,J07CA12,diphtheria-pertussis-poliomyelitis-tetanus-hepatitis b,DTaP-HB-IPV PEDIARIX GSK,International,Added,2022-03-31,https://www.fda.gov/media/79830/download,
02231343,Health_Canada,02231343,66128512,Pentacel,7511000087107,PENTACEL powder and suspension for suspension for injection Sanofi Pasteur Limited (real clinical drug),powder for solution AND liquid,intramuscular,733026001,Vial (unit of presentation),,11,diphtheria toxoid 15 LF / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 20 mcg / 0.5 mL + fimbriae (b. pertussis antigen) 5 mcg / 0.5 mL + haemophilus influenzae type b-prp 10 mcg / 0.5 mL + inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney 40 unit / 0.5 mL + inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1 8 unit / 0.5 mL + inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett 32 unit / 0.5 mL + pertactin (b. pertussis virulence factor) 3 mcg / 0.5 mL + pertussis toxoid 20 mcg / 0.5 mL + tetanus protein 30 mcg / 0.5 mL + tetanus toxoid 5 LF / 0.5 mL powder for solution or liquid for injection,Sanofi Pasteur Limited,7931000087106,Pediatric vaccine product containing only diphtheria standard dose + tetanus + acellular pertussis standard dose + inactivated human poliovirus + Haemophilus influenzae type b antigens (medicinal product),Diphtheria + Tetanus + Pertussis + Polio + Hib pediatric,DTaP-IPV-Hib ped,871887006,Vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and Human poliovirus antigens (medicinal product),DTaP-IPV-Hib,DTaP-IPV-Hib,J07CA06,dipht-hemoph influen b-pertuss-polio-tetanus,DTaP-IPV-Hib PENTACEL SP,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00015424.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50651
02534797,Health_Canada,02534797,66128512,Pentacel,7511000087107,PENTACEL powder and suspension for suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),,11,diphtheria toxoid 15 LF / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 20 mcg / 0.5 mL + fimbriae (b. pertussis antigen) 5 mcg / 0.5 mL + haemophilus influenzae type b-prp 10 mcg / 0.5 mL + pertactin (b. pertussis virulence factor) 3 mcg / 0.5 mL + pertussis toxoid 20 mcg / 0.5 mL + poliovirus type 1 mahoney (inactivated) 29 unit / 0.5 mL + poliovirus type 2 mef1 (inactivated) 7 unit / 0.5 mL + poliovirus type 3 saukett (inactivated) 26 unit / 0.5 mL + tetanus protein 30 mcg / 0.5 mL + tetanus toxoid 5 LF / 0.5 mL suspension for injection,Sanofi Pasteur Limited,7931000087106,Pediatric vaccine product containing only diphtheria standard dose + tetanus + acellular pertussis standard dose + inactivated human poliovirus + Haemophilus influenzae type b antigens (medicinal product),Diphtheria + Tetanus + Pertussis + Polio + Hib pediatric,DTaP-IPV-Hib ped,871887006,Vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and Human poliovirus antigens (medicinal product),DTaP-IPV-Hib,DTaP-IPV-Hib,J07CA06,dipht-hemoph influen b-pertuss-polio-tetanus,DTaP-IPV-Hib PENTACEL SP,Marketed,Added,2024-04-03,https://pdf.hres.ca/dpd_pm/00069515.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102369
22181000087103,SNOMED-CT,,,Pentavac,22181000087103,PENTAVAC PFS 0.5 milliliter suspension for injection Serum Institute of India LTD (real clinical drug),,,,,,,,Serum Instutute of India Ltd.,20591000087106,Pediatric vaccine product containing only diptheria standard dose + pertussis standard dose + tetanus + hepatitis B + Haemophilus influenzae type b antigens (medicinal product),Diphtheria + Pertussis + Tetanus + Hepatitis B + Hib pediatric,DPT-HB-Hib ped,871886002,Vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Haemophilus influenzae type B and Hepatitis B virus antigens (medicinal product),Diphtheria + Pertussis + Tetanus + Hepatitis B + Hib,DPT-HB-Hib,J07CA11,diphtheria-haemophilus influenzae b-pertussis-tetanus-hepatitis b,DPT-HB-Hib PENTAVAC PFS SII,International,Added,2022-03-31,http://www.hpra.ie/img/uploaded/swedocuments/39e005ed-4aaf-4c5a-9fbf-22e16924b480.pdf,
SCT TBD 40,SNOMED-CT,,,Plague Vaccine,SCT TBD 40,PLAGUE VACCINE inactivated Yersinia pestis antigen vaccine for injection Greer Laboritories Inc. (real clinical drug),,,,,,1,,Greer Laboratories Inc.,871718002,Vaccine product containing only Yersinia pestis antigen (medicinal product),Plague vaccine,Plag-IA,840549009,Vaccine product containing Yersinia pestis antigen (medicinal product),Plague,PLAG,J07AK01,"plague, inactivated, whole cell",PLAGUE,International,Added,2024-11-27,,
02231259,Health_Canada,02231259,66124784,Pneumo 23,7631000087101,Pneumo 23 solution for injection Sanofi Pasteur SA (real clinical drug),liquid,subcutaneous OR intramuscular,733020007,Syringe (unit of presentation),0.5ml prefilled syringe,23,pneumococcal polysaccharide serotype 1 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 10a 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 11a 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 12f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 14 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 15b 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 17f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 18c 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 19a 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 19f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 2 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 20 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 22f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 23f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 3 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 33f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 4 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 5 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 6b 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 7f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 8 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 9n 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 9v 25 mcg / 0.5 mL liquid for injection,Sanofi Pasteur Limited,7251000087108,Vaccine product containing only pneumococcal 23 serotypes polysaccharide unconjugated antigens (medicinal product),Pneumococcal polysaccharide 23-valent,Pneu-P-23,981000221107,Vaccine product containing only Streptococcus pneumoniae antigen (medicinal product),Pneumococcal,Pneu,J07AL02,"pneumococcus, purified polysacc.antigen conjugated",Pneu-P-23 PNEUMO 23 SP,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00006330.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50566
02436442,Health_Canada,02436442,66124785,Pneumovax 23,7641000087107,Pneumovax 23 solution for injection Merck Canada Inc. (real clinical drug),solution,subcutaneous OR intramuscular,733020007,Syringe (unit of presentation),Single-dose prefilled syringe,23,pneumococcal polysaccharide serotype 1 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 10a 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 11a 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 12f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 14 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 15b 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 17f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 18c 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 19a 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 19f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 2 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 20 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 22f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 23f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 3 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 33f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 4 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 5 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 6b 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 7f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 8 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 9n 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 9v 25 mcg / 0.5 mL solution for injection,Merck Canada Inc,7251000087108,Vaccine product containing only pneumococcal 23 serotypes polysaccharide unconjugated antigens (medicinal product),Pneumococcal polysaccharide 23-valent,Pneu-P-23,981000221107,Vaccine product containing only Streptococcus pneumoniae antigen (medicinal product),Pneumococcal,Pneu,J07AL01,"pneumococcus, purified polysaccharides antigen",Pneu-P-23 PNEUMOVAX 23 Merck,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00035855.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92078
00431648,Health_Canada,00431648,66124785,Pneumovax 23,7641000087107,Pneumovax 23 solution for injection Merck Canada Inc. (real clinical drug),solution,subcutaneous OR intramuscular,733026001,Vial (unit of presentation),Single dose vials,23,pneumococcal polysaccharide serotype 1 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 10a 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 11a 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 12f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 14 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 15b 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 17f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 18c 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 19a 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 19f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 2 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 20 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 22f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 23f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 3 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 33f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 4 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 5 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 6b 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 7f 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 8 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 9n 25 mcg / 0.5 mL + pneumococcal polysaccharide serotype 9v 25 mcg / 0.5 mL solution for injection,Merck Canada Inc,7251000087108,Vaccine product containing only pneumococcal 23 serotypes polysaccharide unconjugated antigens (medicinal product),Pneumococcal polysaccharide 23-valent,Pneu-P-23,981000221107,Vaccine product containing only Streptococcus pneumoniae antigen (medicinal product),Pneumococcal,Pneu,J07AL02,"pneumococcus, purified polysacc.antigen conjugated",Pneu-P-23 PNEUMOVAX 23 Merck,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00035855.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2969
02533286,Health_Canada,02533286,,Prehevbrio,379081000087107,PREHEVBRIO 10 micrograms per milliliter suspension for injection VBI Vaccines Inc. (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),,1,hepatitis b surface antigen (recombinant) 10 mcg / mL suspension for injection,Vbi Vaccines Inc.,1296678009,"Vaccine product containing only S, preS1, preS2 Hepatitis B virus recombinant surface antigens (medicinal product)",Hepatatis B recombinant - 3,HBR-3,871822003,Vaccine product containing only Hepatitis B virus antigen (medicinal product),Hepatitis B antigen,HB Ag,J07BC01,"hepatitis b, purified antigen",HB  PREHEVBRIO VBI,Approved,Added,2023-06-23,https://pdf.hres.ca/dpd_pm/00069966.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102228
02244081,Health_Canada,02244081,66124786,Prevnar,7651000087105,Prevnar 16 micrograms per 0.5 milliliter suspension for injection Pfizer Canada Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Single dose pre-filled syringes and vials,8,corynebacterium diphtheriae crm-197 protein 20 mcg / 0.5 mL + pneumococcal polysaccharide serotype 14 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 18c 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 19f 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 23f 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 4 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 6b 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 9v 2 mcg / 0.5 mL suspension for injection,Pfizer Canada Ulc,1052328007,"Vaccine product containing only Streptococcus pneumoniae Danish serotype 4, 6B, 9V, 14, 18C, 19F, and 23F capsular polysaccharide antigens conjugated (medicinal product)",Pneumococcal conjugated 7-valent,Pneu-C-7,981000221107,Vaccine product containing only Streptococcus pneumoniae antigen (medicinal product),Pneumococcal,Pneu,J07AL02,"pneumococcus, purified polysacc.antigen conjugated",Pneu-C-7 PREVNAR Pfiz,Cancelled post market,Modified,2024-04-05,https://pdf.hres.ca/dpd_pm/00011596.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68040
02335204,Health_Canada,02335204,66124833,Prevnar 13,7681000087102,Prevnar 13 suspension for injection Pfizer Canada ULC (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),,14,corynebacterium diphtheriae crm-197 protein 34 mcg / 0.5 mL + pneumococcal polysaccharide serotype 1 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 14 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 18c 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 19a 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 19f 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 23f 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 3 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 4 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 5 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 6a 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 6b 4.4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 7f 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 9v 2.2 mcg / 0.5 mL suspension for injection,Pfizer Canada Ulc,51451000087105,"Vaccine product containing only Streptococcus pneumoniae Danish serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F capsular polysaccharide antigens conjugated (medicinal product)",Pneumococcal conjugated 13-valent,Pneu-C-13,981000221107,Vaccine product containing only Streptococcus pneumoniae antigen (medicinal product),Pneumococcal,Pneu,J07AL02,"pneumococcus, purified polysacc.antigen conjugated",Pneu-C-13 PREVNAR 13 Pfiz,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00011596.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82074
02527049,Health_Canada,02527049,66128549,Prevnar 20,37881000087105,PREVNAR 20 0.5 milliliter suspension for injection Pfizer Canada ULC (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),"Single-dose prefilled syringe,0.5 ml",21,corynebacterium diphtheriae crm-197 protein 51 mcg / 0.5 mL + pneumococcal polysaccharide serotype 1 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 10a 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 11a 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 12f 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 14 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 15b 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 18c 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 19a 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 19f 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 22f 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 23f 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 3 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 33f 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 4 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 5 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 6a 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 6b 4.4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 7f 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 8 2.2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 9v 2.2 mcg / 0.5 mL suspension for injection,Pfizer Canada Ulc,1252709000,"Vaccine product containing only Streptococcus pneumoniae Danish serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F capsular polysaccharide antigens conjugated (medicinal product)",Pneumococal conjugated 20 valent,Pneu-C-20,981000221107,Vaccine product containing only Streptococcus pneumoniae antigen (medicinal product),Pneumococcal,Pneu,J07AL02,"pneumococcus, purified polysacc.antigen conjugated",Pneu-C-20 PREVNAR 20 Pfiz,Marketed,Added,2022-11-24,https://pdf.hres.ca/dpd_pm/00065729.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101610
02239208,Health_Canada,02239208,66124834,Priorix,7171000087106,PRIORIX powder and diluent for solution for injection GlaxoSmithKline Inc. (real clinical drug),kit AND powder for solution,subcutaneous OR intramuscular,733026001,Vial (unit of presentation),,4,measles virus vaccine live attenuated 1000 CCID50 / 0.5 mL with mumps virus vaccine live attenuated (jeryl lynn strain) 10000 CCID50 / 0.5 mL with rubella virus vaccine live attenuated (wistar ra27/3 strain) 1000 CCID50 / 0.5 mL with water 0.5 ml kit (powder for solution) for injection,Glaxosmithkline Inc,2241000221103,Vaccine product containing only live attenuated Measles morbillivirus and Mumps orthorubulavirus and Rubella virus antigens (medicinal product),Measles + Mumps + Rubella live attenuated,MMR live,871831003,Vaccine product containing only Measles morbillivirus and Mumps orthorubulavirus and Rubella virus antigens (medicinal product),Measles + Mumps + Rubella,MMR,J07BD52,"measles, combin. with mumps and rubella, live attenuated",MMR PRIORIX GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00052672.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62666
02297884,Health_Canada,02297884,66128069,Priorix-Tetra,7181000087108,PRIORIX-TETRA powder and solution for injection GlaxoSmithKline Inc. (real clinical drug),powder for solution,intramuscular OR subcutaneous,733026001,Vial (unit of presentation),,4,measles virus vaccine live attenuated 1000 CCID50 / 0.5 mL + mumps virus vaccine live attenuated (jeryl lynn strain) 25118.9 CCID50 / 0.5 mL + rubella virus vaccine live attenuated (wistar ra27/3 strain) 1000 CCID50 / 0.5 mL + varicella-zoster virus vaccine live attenuated (oka-strain) 1995.2623 CCID50 / 0.5 mL powder for solution for injection,Glaxosmithkline Inc,2251000221101,Vaccine product containing only live attenuated Measles morbillivirus and Mumps orthorubulavirus and Rubella virus and Human alphaherpesvirus 3 antigens (medicinal product),Measles + Mumps + Rubella + Varicella live attenuated,MMR-Var live,871908002,Vaccine product containing only Human alphaherpesvirus 3 and Measles morbillivirus and Mumps orthorubulavirus and Rubella virus antigens (medicinal product),Measles + Mumps + Rubella + Varicella,MMR Var,J07BD54,"measles, combinations with mumps, rubella and varicella, live attenuated",MMR-Var PRIORIX-TETRA GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00052673.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78322
02399229,Health_Canada,02399229,66128068,Proquad,19441000087102,ProQuad powder and diluent for solution for injection Merck Canada Inc. (real clinical drug),powder for solution,subcutaneous,733026001,Vial (unit of presentation),,4,measles virus live attenuated (edmonston strain) 3 Log10 TCID50 / 0.5 mL + mumps virus live attenuated (jeryl lynn strain) 4.3 Log10 TCID50 / 0.5 mL + rubella virus live attenuated (wistar ra27/3 strain) 3 Log10 TCID50 / 0.5 mL + varicella virus live attenuated (oka/merck strain) 3.99 Log10 PFU / 0.5 mL powder for solution for injection,Merck Canada Inc,2251000221101,Vaccine product containing only live attenuated Measles morbillivirus and Mumps orthorubulavirus and Rubella virus and Human alphaherpesvirus 3 antigens (medicinal product),Measles + Mumps + Rubella + Varicella live attenuated,MMR-Var live,871908002,Vaccine product containing only Human alphaherpesvirus 3 and Measles morbillivirus and Mumps orthorubulavirus and Rubella virus antigens (medicinal product),Measles + Mumps + Rubella + Varicella,MMR Var,J07BD54,"measles, combinations with mumps, rubella and varicella, live attenuated",MMR-Var ProQuad Merck,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00057005.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88411
33451000087108,SNOMED-CT,,,QazCovid-in,33451000087108,QazCovid-in COVID-19 whole inactivated virus vaccine (real medicinal product),,,,,,,,Kazakhstan RIBSP,1157024006,Vaccine product containing only inactivated whole severe acute respiratory syndrome coronavirus 2 antigen (medicinal product),COVID-19 whole inactivated virus,COVID-19 WIV,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN03,"covid-19, inactivated virus",COVID-19 QazCovid-in,International,Added,2022-03-31,https://covid19.trackvaccines.org/vaccines/30/,
SCT TBD 43,SNOMED-CT,,,Qdenga,SCT TBD 43,Qdenga tetravalent live-attenuated dengue virus vaccine (real medicinal product),powder and solvent for solution for injection,,733020007,Syringe (unit of presentation),,4,,Takeda GmbH,SCT TBD 25,Vaccine product containing only live-attenuated dengue virus 4 antigen (medicinal product),Dengue live attenuated - 4,Deng-LA-4,871720004,Vaccine product containing only Dengue virus antigen (medicinal product),Dengue,Deng,J07BX04,dengue virus vaccines,Dengue Qdenga,International,Added,2024-12-11,https://www.ema.europa.eu/en/documents/product-information/qdenga-epar-product-information_en.pdf,
02230946,Health_Canada,02230946,66124787,Quadracel,7471000087101,QUADRACEL suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),,9,diphtheria toxoid 15 LF / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 20 mcg / 0.5 mL + fimbriae (b. pertussis antigen) 5 mcg / 0.5 mL + inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney 40 unit / 0.5 mL + inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1 8 unit / 0.5 mL + inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett 32 unit / 0.5 mL + pertactin (b. pertussis virulence factor) 3 mcg / 0.5 mL + pertussis toxoid 20 mcg / 0.5 mL + tetanus toxoid 5 LF / 0.5 mL suspension for injection,Sanofi Pasteur Limited,7881000087101,Pediatric vaccine product containing diphtheria standard dose + tetanus + acellular pertussis standard dose + inactivated human poliovirus antigens (medicinal product),Diphtheria + Tetanus + Pertussis + Polio pediatric,DTaP-IPV ped,871878002,Vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (medicinal product),Diphtheria + Tetanus + aPertussis + Polio,DTaP-IPV,J07CA02,diphtheria-pertussis-poliomyelitis-tetanus,DTaP-IPV QUADRACEL SP,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00013848.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50224
02534789,Health_Canada,02534789,66124787,Quadracel,7471000087101,QUADRACEL suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),,9,diphtheria toxoid 15 LF / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 20 mcg / 0.5 mL + fimbriae types 2 and 3 (fim - b. pertussis antigen) 5 mcg / 0.5 mL + pertactin (b. pertussis virulence factor) 3 mcg / 0.5 mL + pertussis toxoid 20 mcg / 0.5 mL + poliovirus type 1 mahoney (inactivated) 29 unit / 0.5 mL + poliovirus type 2 mef1 (inactivated) 7 unit / 0.5 mL + poliovirus type 3 saukett (inactivated) 26 unit / 0.5 mL + tetanus toxoid 5 LF / 0.5 mL suspension for injection,Sanofi Pasteur Limited,7881000087101,Pediatric vaccine product containing diphtheria standard dose + tetanus + acellular pertussis standard dose + inactivated human poliovirus antigens (medicinal product),Diphtheria + Tetanus + Pertussis + Polio pediatric,DTaP-IPV ped,871878002,Vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (medicinal product),Diphtheria + Tetanus + aPertussis + Polio,DTaP-IPV,J07CA02,diphtheria-pertussis-poliomyelitis-tetanus,DTaP-IPV QUADRACEL SP,Marketed,Added,2024-09-19,https://pdf.hres.ca/dpd_pm/00013848.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102368
02267667,Health_Canada,02267667,66124788,Rabavert,33231000087100,RABAVERT 2.5 international units per milliliter powder for solution for injection Bavarian Nordic AS (real clinical drug),powder for solution,intramuscular,733026001,Vial (unit of presentation),,1,inactivated rabies virus (flury lep) 2.5 unit / mL powder for solution for injection,Bavarian Nordic As,1131000221109,Vaccine product containing only inactivated whole Rabies lyssavirus antigen (medicinal product),Rabies inactivated whole virus,RAB-IV,871726005,Vaccine product containing only Rabies lyssavirus antigen (medicinal product),Rabies,Rab,J07BG01,"rabies, inactivated, whole virus",Rab RABAVERT BN,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00062278.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75308
02561484,Health_Canada,02561484,66124789,Recombivax Hb,6951000087100,RECOMBIVAX HB 10 micrograms per milliliter suspension for injection Merck Canada Inc. (real clinical drug),solution,intramuscular,733020007,Syringe (unit of presentation),Single-use prefilled syringe,1,hepatitis b surface antigen (recombinant) 10 mcg / 1 mL solution for injection,Merck Canada Inc,8771000087109,Adult vaccine product containing only Hepatitis B virus regular strength antigen (medicinal product),Hepatitis B adult,HB adult,871822003,Vaccine product containing only Hepatitis B virus antigen (medicinal product),Hepatitis B,HB,J07BC01,"hepatitis b, purified antigen",HB RECOMBIVAX HB Merck,Approved,Added,2025-11-15,https://pdf.hres.ca/dpd_pm/00082058.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106444
6931000087109,SNOMED-CT,02243676,66124790,Recombivax Hb,6931000087109,RECOMBIVAX HB 5 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Preservative-free,1,hepatitis b surface antigen (recombinant) 10 mcg / mL suspension for injection,Merck Canada Inc,9831000087108,Pediatric vaccine product containing only Hepatitis B virus low strength antigen (medicinal product),Hepatitis B pediatric,HB ped,871822003,Vaccine product containing only Hepatitis B virus antigen (medicinal product),Hepatitis B,HB,J07BC01,"hepatitis b, purified antigen",HB RECOMBIVAX HB pediatric Merck,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00016542.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67606
6951000087100,SNOMED-CT,02243676,66124791,Recombivax Hb,6951000087100,RECOMBIVAX HB 10 micrograms per milliliter suspension for injection Merck Canada Inc. (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Preservative-free,1,hepatitis b surface antigen (recombinant) 10 mcg / mL suspension for injection,Merck Canada Inc,8771000087109,Adult vaccine product containing only Hepatitis B virus regular strength antigen (medicinal product),Hepatitis B adult,HB adult,871822003,Vaccine product containing only Hepatitis B virus antigen (medicinal product),Hepatitis B,HB,J07BC01,"hepatitis b, purified antigen",HB RECOMBIVAX HB Merck,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00016542.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67606
02245977,Health_Canada,02245977,66124789,Recombivax Hb,6941000087103,RECOMBIVAX HB 40 micrograms per milliliter suspension for injection Merck Canada Inc. (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),"Adult dialysis, preservative-free",1,hepatitis b surface antigen (recombinant) 40 mcg / mL suspension for injection,Merck Canada Inc,8781000087106,Adult and dialysis vaccine product containing only Hepatitis B virus high strength antigen (medicinal product),Hepatitis B dial,HB dial,871822003,Vaccine product containing only Hepatitis B virus antigen (medicinal product),Hepatitis B,HB,J07BC01,"hepatitis b, purified antigen",HB RECOMBIVAX HB dialysis Merck,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00016542.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70103
02561476,Health_Canada,02561476,66124790,Recombivax Hb,6931000087109,RECOMBIVAX HB 5 micrograms per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug),solution,intramuscular,733020007,Syringe (unit of presentation),Single-use prefilled syringe,1,hepatitis b surface antigen (recombinant) 5 mcg / 0.5 mL solution for injection,Merck Canada Inc,9831000087108,Pediatric vaccine product containing only Hepatitis B virus low strength antigen (medicinal product),Hepatitis B pediatric,HB ped,871822003,Vaccine product containing only Hepatitis B virus antigen (medicinal product),Hepatitis B,HB,J07BC01,"hepatitis b, purified antigen",HB RECOMBIVAX HB pediatric Merck,Approved,Added,2025-11-15,https://pdf.hres.ca/dpd_pm/00082058.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106443
02300591,Health_Canada,02300591,,Rotarix,7191000087105,ROTARIX 1000000 units per 1.5 milliliter oral suspension GlaxoSmithKline Inc. (real clinical drug),suspension,oral,733024003,Tube (unit of presentation),,1,"rotavirus vaccine (rix4414 strain), live, oral, attenuated (human) 1000000 CCID50 / 1.5 mL oral suspension",Glaxosmithkline Inc,7811000087105,Vaccine product containing only Rotavirus 1 serotype antigen (medicinal product),Rotavirus monovalent,Rota-1,871761004,Vaccine product containing only Rotavirus antigen (medicinal product),Rotavirus,Rota,J07BH01,"rota virus, live attenuated",Rota ROTARIX GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00060847.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78588
02284413,Health_Canada,02284413,,Rotateq,7201000087107,RotaTeq 115000000 units per 2 milliliter oral solution Merck Canada Inc. (real clinical drug),solution,oral,733024003,Tube (unit of presentation),"Rotavirus vaccine, live, oral, pentavalent. prefilled 2ml unit dose tube",5,human-bovine rotavirus reassortant type g1 2210000 unit / 2 mL + human-bovine rotavirus reassortant type g2 2840000 unit / 2 mL + human-bovine rotavirus reassortant type g3 2220000 unit / 2 mL + human-bovine rotavirus reassortant type g4 2040000 unit / 2 mL + human-bovine rotavirus reassortant type p1(8) 2290000 unit / 2 mL oral solution,Merck Canada Inc,7821000087102,Vaccine product containing only Rotavirus 5 serotypes antigens (medicinal product),Rotavirus pentavalent,Rota-5,871761004,Vaccine product containing only Rotavirus antigen (medicinal product),Rotavirus,Rota,J07BH02,"rota virus, pentavalent, live, reassorted",Rota RotaTeq Merck,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00043662.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76999
02468425,Health_Canada,02468425,66123642,Shingrix,23011000087103,SHINGRIX 50 micrograms per 0.5 milliliter powder and suspension for suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),"Herpes zoster vaccine (non-live recombinant, as01b adjuvanted)",1,varicella-zoster virus glycoprotein e antigen 50 mcg / 0.5 mL suspension for injection,Glaxosmithkline Inc,56011000087109,Vaccine product containing only Human alphaherpesvirus 3 recombinant surface glycoprotein E antigen for herpes zoster prevention (medicinal product),RZV E antigen,RZV-E,28451000087102,Vaccine product containing only Human alphaherpesvirus 3 antigen for herpes zoster prevention (medicinal product),Zoster,Zos,J07BK,varicella zoster vaccines,RZV SHINGRIX GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00063712.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95685
31301000087101,SNOMED-CT,,,Sinopharm-BIBP,31301000087101,SINOPHARM-BIBP COVID-19 whole inactivated virus vaccine (real medicinal product),,,,,,,,Sinopharm and Beijing Institute of Biological Products Co-Ltd,1157024006,Vaccine product containing only inactivated whole severe acute respiratory syndrome coronavirus 2 antigen (medicinal product),COVID-19 whole inactivated virus,COVID-19 WIV,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN03,"covid-19, inactivated virus",COVID-19 SINOPHARM-BIBP,International,Added,2022-03-31,https://extranet.who.int/pqweb/vaccines/who-recommendation-covid-19-vaccine-bibp,
33201000087108,SNOMED-CT,,,Sinopharm-WIBP,33201000087108,SINOPHARM-WIBP COVID-19 whole inactivated virus vaccine (real medicinal product),,,,,,,,Sinopharm and Wuhan Institute of Biological Products,1157024006,Vaccine product containing only inactivated whole severe acute respiratory syndrome coronavirus 2 antigen (medicinal product),COVID-19 whole inactivated virus,COVID-19 WIV,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN03,"covid-19, inactivated virus",COVID-19 SINOPHARM-WIBP,International,Added,2022-03-31,https://covid19.trackvaccines.org/vaccines/16/,
SCT TBD 31,SNOMED-CT,,,Sinovac Biotech EV71,SCT TBD 31,SINOVAC BIOTECH inactivated Enterovirus 71 C4 genogroup antigen vaccine,,,,,,,,Sinovac Biotech,SCT TBD 33,Vaccine product containing inactivated Enterovirus 71 antigen,Enterovirus 71 inactivated antigen,EV17-IA,51591000087104,Vaccine product containing only Enterovirus A71 antigen (medicinal product),Enterovirus antigen,EV71,J07BX06,enterovirus 17 vaccines,EV17 SINOVAC,International,Added,2024-06-03,,
34591000087100,SNOMED-CT,,,Soberana 02,34591000087100,Soberana 02 COVID-19 recombinant spike protein vaccine (real medicinal product),,,,,,,,Instituto Finlay de Vacunas,1162643001,Vaccine product containing only Severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN04,covid-19 protein subunit,COVID-19 SOBERANA 02 IFV,International,Added,2022-11-20,https://covid19.trackvaccines.org/vaccines/52/,
02527685,Health_Canada,02527685,66128581,Spikevax 0.10 mg/mL (COVID-19),35651000087105,SPIKEVAX (original strain) messenger ribonucleic acid 0.10 milligrams per 1 milliliter dispersion for injection Moderna Biopharma Canada Corporation (real clinical drug),dispersion,intramuscular,733026001,Vial (unit of presentation),2.5 ml vial,1,elasomeran (ba.4) 0.1 mg / mL dispersion for injection,Moderna Biopharma Canada Corporation,1119349007,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA,COVID-19 mRNA,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 SPIKEVAX  0.10 mg/mL Mod,Cancelled post market,Added,2022-11-20,https://pdf.hres.ca/dpd_pm/00066643.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101673
02510014,Health_Canada,02510014,66128581,Spikevax 0.2mg/mL (COVID-19),28571000087109,SPIKEVAX (original strain) messenger ribonucleic acid 0.20 milligrams per 1 milliliter dispersion for injection Moderna Biopharma Canada Corporation (real clinical drug),dispersion,intramuscular,733026001,Vial (unit of presentation),5 ml vial,1,elasomeran (ba.4) 0.2 mg / mL dispersion for injection,Moderna Biopharma Canada Corporation,1119349007,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA,COVID-19 mRNA,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 SPIKEVAX (original strain) 0.20 mg/mL mRNA Mod,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00066643.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99927
02530252,Health_Canada,02530252,66128581,Spikevax Bivalent (Original / Omicron BA.1) 0.10 mg/mL (COVID-19),37311000087109,SPIKEVAX Bivalent (Original / Omicron BA.1) messenger ribonucleic acid 0.10 milligrams per 1 milliliter dispersion for injection Moderna Biopharma Canada Corporation (real clinical drug),dispersion,intramuscular,733026001,Vial (unit of presentation),2.5 ml multidose vial,2,elasomeran (ba.4) 0.05 mg / mL + imelasomeran (ba.1) 0.05 mg / mL dispersion for injection,Moderna Biopharma Canada Corporation,1119349007,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA,COVID-19 mRNA,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 SPIKEVAX Original / Omicron BA.1 0.10 mg/mL mRNA Mod,Cancelled post market,Added,2022-11-20,https://pdf.hres.ca/dpd_pm/00067127.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101943
38591000087106,Health_Canada,02532352,66128581,Spikevax Bivalent (Original / Omicron BA.4/BA.5) 0.05 mg/mL (COVID-19),38591000087106,SPIKEVAX Bivalent (Original / Omicron BA.4/BA.5) messenger ribonucleic acid 10 micrograms per 0.2 milliliter dispersion for injection Moderna Biopharma Canada Corporation (real clinical drug),dispersion,intramuscular,733026001,Vial (unit of presentation),2.5 ml multidose vial,2,davesomeran (ba.5) 0.05 mg / mL + elasomeran (ba.4) 0.05 mg / mL dispersion for injection,Moderna Biopharma Canada Corporation,33581000087104,Pediatric vaccine product containing only Severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA Pediatric,COVID-19 mRNA Ped,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 SPIKEVAX Bivalent (Original / Omicron BA.4/BA.5) messenger ribonucleic acid 10 micrograms per 0.2 milliliter dispersion for injection Moderna Therapeutics Inc. (real clinical drug),Cancelled post market,Added,2022-12-11,https://pdf.hres.ca/dpd_pm/00063329.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102139
02532352,Health_Canada,02532352,66128581,Spikevax Bivalent (Original / Omicron BA.4/BA.5) 0.10 mg/mL (COVID-19),37651000087101,SPIKEVAX Bivalent (Original / Omicron BA.4/BA.5) messenger ribonucleic acid 0.10 milligrams per 1 milliliter dispersion for injection Moderna Biopharma Canada Corporation (real clinical drug),dispersion,intramuscular,733026001,Vial (unit of presentation),2.5 ml multidose vial,2,davesomeran (ba.5) 0.05 mg / mL + elasomeran (ba.4) 0.05 mg / mL dispersion for injection,Moderna Biopharma Canada Corporation,1119349007,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid (medicinal product),COVID-19 mRNA,COVID-19 mRNA,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 SPIKEVAX Original / Omicron BA.4/BA.5) 0.10 mg/mL Mod,Cancelled post market,Added,2022-11-20,https://pdf.hres.ca/dpd_pm/00067971.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102139
02541270,Health_Canada,02541270,66128581,Spikevax KP.2,60671000087102,SPIKEVAX messenger ribonucleic acid 0.10 milligrams per 1 milliliter dispersion for injection Moderna Biopharma Canada Corporation (real clinical drug),dispersion,intramuscular,733026001,Vial (unit of presentation),2.5 ml multidose vial,1,andusomeran 0.1 mg / mL dispersion for injection,Moderna Biopharma Canada Corporation,1162643001,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 SPIKEVAX 0.10 mg/mL mRNA Mod,Marketed,Modified,2024-12-14,https://pdf.hres.ca/dpd_pm/00078019.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102992
02557770,Health_Canada,02557770,66128581,Spikevax LP.8.1,60671000087102,SPIKEVAX messenger ribonucleic acid 0.10 milligrams per 1 milliliter dispersion for injection Moderna Biopharma Canada Corporation (real clinical drug),dispersion,intramuscular,733020007,Syringe (unit of presentation),Single-dose pre-filled syringe,1,andusomeran 50 mcg / 0.5 mL dispersion for injection,Moderna Biopharma Canada Corporation,1162643001,Vaccine product containing only severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN01,"covid-19, rna-based vaccine",COVID-19 SPIKEVAX LP.8.1 0.10 mg/mL mRNA Mod,Marketed,Added,2025-08-23,https://pdf.hres.ca/dpd_pm/00081474.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106107
34601000087108,SNOMED-CT,,,SpikoGen,34601000087108,SpikoGen COVID-19 recombinant spike protein vaccine (real medicinal product),,,,,,,,Vaxine/CinnaGen Co,1162643001,Vaccine product containing only Severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN04,covid-19 protein subunit,COVID-19 SpikeOgen,International,Added,2022-11-20,https://covid19.trackvaccines.org/vaccines/8/,
33461000087106,SNOMED-CT,,,Sputnik Light,33461000087106,Sputnik Light COVID-19 non-replicating vector vaccine (real medicinal product),,,,,,,,Gamaleya Research Institute,29061000087103,Vaccine product containing only recombinant non-replicating viral vector encoding severe acute respiratory syndrome coronavirus 2 spike protein (medicinal product),COVID-19 non-replicating vector,COVID-19 NRV,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN02,"covid-19, viral vector, non-replicating",COVID-19 Sputnik Light,International,Added,2022-03-31,https://covid19.trackvaccines.org/vaccines/126/,
31341000087103,SNOMED-CT,,,Sputnik V,31341000087103,Sputnik V COVID-19 non-replicating vector vaccine (real medicinal product),,,,,,,,Gamaleya Research Institute,29061000087103,Vaccine product containing only recombinant non-replicating viral vector encoding severe acute respiratory syndrome coronavirus 2 spike protein (medicinal product),COVID-19 non-replicating vector,COVID-19 NRV,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN02,"covid-19, viral vector, non-replicating",COVID-19 Sputnik V,International,Added,2022-03-31,https://covid19.trackvaccines.org/vaccines/12/,
02510936,Health_Canada,02510936,,Supemtek,35661000087108,Supemtek 45 micrograms per 0.5 milliliter solution for injection Sanofi Pasteur Limited (real clinical drug),solution,intramuscular,733020007,Syringe (unit of presentation),Prefilled syringe,4,recombinant haemagglutinin protein-strain a (h1n1) 45 mcg / 0.5 mL + recombinant haemagglutinin protein-strain a (h3n2) 45 mcg / 0.5 mL + recombinant haemagglutinin protein-strain b (victoria) 45 mcg / 0.5 mL + recombinant haemagglutinin protein-strain b (yamagata) 45 mcg / 0.5 mL solution for injection,Sanofi Pasteur Limited,2261000221104,Vaccine product containing only influenza A virus subtypes H1N1 and H3N2 and influenza B virus Victoria and Yamagata lineage antigens (medicinal product),Influenza H1N1+H3N2+B+VY,RInf-4,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf SUPEMTEK SP - Pre-filled syringe,Cancelled post market,Modified,2022-11-24,https://pdf.hres.ca/dpd_pm/00065594.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100014
02438364,Health_Canada,02438364,,Synagis,19411000087103,SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),1ml single use vial,1,palivizumab 100 mg / mL solution for injection,Astrazeneca Canada Inc,766147000,Product containing precisely palivizumab 100 milligram/1 vial powder for conventional release solution for injection (clinical drug),Respiratory syncytial virus mAb palivizumab high dose,RSV-mAb palivizumab HD,61231000087107,Product containing only monoclonal antibody to Orthopneumovirus hominis (medicinal product),RSV monoclonal antibody,RSV mAb,J06BD01,palivizumab,RSVmAb SYNAGIS BI,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00062121.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92274
02438372,Health_Canada,02438372,,Synagis,57871000087109,SYNAGIS 100 milligrams per milliliter solution for injection AstraZeneca Canada Inc. (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),0.5ml single use vial,1,palivizumab 50 mg / 0.5 mL solution for injection,Astrazeneca Canada Inc,766148005,Product containing precisely palivizumab 50 milligram/1 vial powder for conventional release solution for injection (clinical drug),Respiratory syncytial virus mAb palivizumab low dose,RSV-mAb palivizumab LD,61231000087107,Product containing only monoclonal antibody to Orthopneumovirus hominis (medicinal product),RSV monoclonal antibody,RSV mAb,J06BD01,palivizumab,RSVmAB SYNAGIS AZC 50mg/0.5mL,Marketed,Modified,2024-09-19,https://pdf.hres.ca/dpd_pm/00062121.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92275
02320541,Health_Canada,02320541,,Synflorix,7671000087104,SYNFLORIX 16 micrograms per 0.5 milliliter suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),,10,pneumococcal polysacc. serot. 18c conjug. to tetanus toxoid carrier prot. 3 mcg / 0.5 mL + pneumococcal polysaccharid serot. 19f conjug. to diphtheria toxoid carrier prot. 3 mcg / 0.5 mL + pneumococcal polysaccharide serotype 1 conjugated to protein d carrier protein 1 mcg / 0.5 mL + pneumococcal polysaccharide serotype 14 conjugated to protein d carrier protein 1 mcg / 0.5 mL + pneumococcal polysaccharide serotype 23f conjugated to protein d carrier protein 1 mcg / 0.5 mL + pneumococcal polysaccharide serotype 4 conjugated to protein d carrier protein 3 mcg / 0.5 mL + pneumococcal polysaccharide serotype 5 conjugated to protein d carrier protein 1 mcg / 0.5 mL + pneumococcal polysaccharide serotype 6b conjugated to protein d carrier protein 1 mcg / 0.5 mL + pneumococcal polysaccharide serotype 7f conjugated to protein d carrier protein 1 mcg / 0.5 mL + pneumococcal polysaccharide serotype 9v conjugated to protein d carrier protein 1 mcg / 0.5 mL suspension for injection,Glaxosmithkline Inc,1052330009,"Vaccine product containing only Streptococcus pneumoniae Danish serotype 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F capsular polysaccharide antigens conjugated (medicinal product)",Pneumococcal conjugated 10-valent,Pneu-C-10,981000221107,Vaccine product containing only Streptococcus pneumoniae antigen (medicinal product),Pneumococcal,Pneu,J07AL02,"pneumococcus, purified polysacc.antigen conjugated",Pneu-C-10 SYNFLORIX GSK,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00053908.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80596
00514462,Health_Canada,00514462,66124793,Td Adsorbed,7371000087109,Td ADSORBED 5 limit of flocculation units and 2 limit of flocculation units per 0.5 milliliter with preservative suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),With preservative,2,diphtheria toxoid adsorbed 2 LF / 0.5 mL + tetanus toxoid adsorbed 5 LF / 0.5 mL suspension for injection,Sanofi Pasteur Limited,871827009,Vaccine product containing only Clostridium tetani and low dose Corynebacterium diphtheriae antigens (medicinal product),Tetanus + Diphtheria adult,Td adult,871826000,Vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae antigens (medicinal product),Tetanus + Diphtheria,Td,J07AM51,"tetanus toxoid, comb. with diphtheria toxoid",Td ADSORBED with preservative SP,Cancelled post market,Modified,2024-04-05,https://pdf.hres.ca/dpd_pm/00020609.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4109
02528401,Health_Canada,02528401,66124793,Td Adsorbed,56391000087101,Td ADSORBED 5 limit of flocculation units and 2 limit of flocculation units per 0.5 milliliter without preservative suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),Preservative-free,2,diphtheria toxoid adsorbed 2 LF / 0.5 mL + tetanus toxoid adsorbed 5 LF / 0.5 mL suspension for injection,Sanofi Pasteur Limited,871827009,Vaccine product containing only Clostridium tetani and low dose Corynebacterium diphtheriae antigens (medicinal product),Tetanus + Diphtheria adult,Td adult,871826000,Vaccine product containing only Clostridium tetani and Corynebacterium diphtheriae antigens (medicinal product),Tetanus + Diphtheria,Td,J07AM51,"tetanus toxoid, comb. with diphtheria toxoid",Td ADSORBED without preservative SP,Marketed,Modified,2024-04-05,https://pdf.hres.ca/dpd_pm/00066636.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101763
00615358,Health_Canada,00615358,66124792,Td Polio Adsorbed,7531000087102,Td Polio Adsorbed suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),,5,diphtheria toxoid 2 LF / 0.5 mL + inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney 40 unit / 0.5 mL + inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1 8 unit / 0.5 mL + inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett 32 unit / 0.5 mL + tetanus toxoid 5 LF / 0.5 mL suspension for injection,Sanofi Pasteur Limited,7911000087101,Adult vaccine product containing only tetanus + diphtheria low dose + inactivated human poliovirus antigens (medicinal product),Tetanus + Diphtheria + Polio adult,Td-IPV adult,871838009,Vaccine product containing only Clostridium tetani and low dose Corynebacterium diphtheriae and inactivated Human poliovirus antigens (medicinal product),Tetanus + Diphtheria + Polio,Td-IPV,J07CA01,diphtheria-poliomyelitis-tetanus,Td-IPV Td Polio Adsorbed SP,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00012130.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5907
23721000087109,SNOMED-CT,,,Tetravac-acellulaire,23721000087109,TETRAVAC-ACELLULAIRE suspension for injection Sanofi Pasteur (real clinical drug),,,,,,,,Sanofi Pasteur Ltd.,7881000087101,Pediatric vaccine product containing diphtheria standard dose + tetanus + acellular pertussis standard dose + inactivated human poliovirus antigens (medicinal product),Diphtheria + Tetanus + Pertussis + Polio pediatric,DTaP-IPV ped,871878002,Vaccine product containing only Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae and Human poliovirus antigens (medicinal product),Diphtheria + Tetanus + aPertussis + Polio,DTaP-IPV,J07CA02,diphtheria-pertussis-poliomyelitis-tetanus,DTaP-IPV TETRAVAC-ACELLULAIRE SP,International,Added,2022-03-31,https://www.drugs.com/uk/tetravac-suspension-for-injection-leaflet.html,
02230273,Health_Canada,02230273,,Tripacel,28721000087103,TRIPACEL suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),,6,diphtheria toxoid 15 LF / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 5 mcg / 0.5 mL + fimbriae (b. pertussis antigen) 5 mcg / 0.5 mL + pertactin (b. pertussis virulence factor) 3 mcg / 0.5 mL + pertussis toxoid 10 mcg / 0.5 mL + tetanus toxoid 5 LF / 0.5 mL suspension for injection,Sanofi Pasteur Limited,7841000087106,Pediatric vaccine product containing only diphtheria standard dose + tetanus + acellular pertussis standard dose antigens (medicinal product),Diphtheria + Tetanus + Pertussis pediatric,DTaP ped,871876003,Vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (medicinal product),Diphtheria + Tetanus + aPertussis,DTaP,J07AJ52,"pertussis, purified antigen, comb. with toxoids",DTaP TRIPACEL SP,Approved,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00020718.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49008
02224143,Health_Canada,02224143,,Tripacel Hybrid,7421000087100,Tripacel Hybrid suspension for injection Sanofi Pasteur Limited (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),,6,diphtheria toxoid 15 LF / 0.5 mL + filamentous haemagglutinin (b. pertussus antigen) 20 mcg / 0.5 mL + fimbriae (b. pertussis antigen) 5 mcg / 0.5 mL + pertactin (b. pertussis virulence factor) 3 mcg / 0.5 mL + pertussis toxoid 20 mcg / 0.5 mL + tetanus toxoid 5 LF / 0.5 mL suspension for injection,Sanofi Pasteur Limited,7841000087106,Pediatric vaccine product containing only diphtheria standard dose + tetanus + acellular pertussis standard dose antigens (medicinal product),Diphtheria + Tetanus + Pertussis pediatric,DTaP ped,871876003,Vaccine product containing only acellular Bordetella pertussis and Clostridium tetani and Corynebacterium diphtheriae antigens (medicinal product),Diphtheria + Tetanus + aPertussis,DTaP,J07AJ52,"pertussis, purified antigen, comb. with toxoids",DTaP TRIPACEL HYBRID SP,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00008524.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43396
23691000087103,SNOMED-CT,,,Tritanrix,23691000087103,Tritanrix suspension for injection GlaxoSmithKline Biologicals (real clinical drug),,,,,,,,GlaxoSmithKline Biologicals,23681000087100,Pediatric vaccine product containing only diptheria standard dose + tetanus + whole cell pertussis standard dose + hepatitis B antigens (medicinal product),Diptheria + Tetanus + Pertussis whole cell + Hepatitis B pediatric,DTwP-HB,20601000087103,Pediatric vaccine product containing only diptheria standard dose + pertussis standard dose + tetanus + hepatitis B antigens (medicinal product),DTP-HB,DTP-HB,J07CA05,diphtheria-hepatitis b-pertussis-tetanus,DTwP-HB Tritanrix GSK,International,Added,2022-03-31,https://www.ema.europa.eu/en/medicines/human/EPAR/tritanrix-hepb,
02468751,Health_Canada,02468751,,Trumenba,23031000087108,Trumenba suspension for injection Pfizer Canada ULC (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Bivalent recombinant lipoprotein (rlp2086) - prefilled syringe,2,neisseria meningitidis grp b recombinant lipoprotein 2086 subfamily a 60 mcg / 0.5 mL + neisseria meningitidis grp b recombinant lipoprotein 2086 subfamily b 60 mcg / 0.5 mL suspension for injection,Pfizer Canada Ulc,1981000221108,Vaccine product containing only Neisseria meningitidis serogroup B antigen (medicinal product),Meningococcal B,Men-B,921000221108,Vaccine product containing only Neisseria meningitidis antigen (medicinal product),Meningococcal,Men,J07AH,meningococcal vaccines,Men-B Trumenba Pfiz,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00051308.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95723
02230578,Health_Canada,02230578,,Twinrix,6971000087106,Twinrix 720 ELISA units HAV and 20 micrograms HBV per milliliter suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,,,,2,"hepatitis a virus, inactivated 720 unit / 1 mL + hepatitis b surface antigen (recombinant) 20 mcg / 1 mL suspension for injection",Glaxosmithkline Inc,24371000087105,Adult vaccine product containing only Hepatitis A + hepatitis B regular strength antigens (medicinal product),Hepatitis A + B adult,HAHB adult,871803007,Vaccine product containing only Hepatitis A and Hepatitis B virus antigens (medicinal product),Hepatitis A + Hepatitis B,HAHB,J07BC20,combinations,HAHB TWINRIX GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00047291.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49687
02237548,Health_Canada,02237548,,Twinrix Junior,6961000087102,Twinrix 360 ELISA units HAV and 10 micrograms HBV per 0.5 milliliter suspension for injection GlaxoSmithKline Inc. (real clinical drug),suspension,intramuscular,,,,2,"hepatitis a virus, inactivated 360 unit / 0.5 mL + hepatitis b surface antigen (recombinant) 10 mcg / 0.5 mL suspension for injection",Glaxosmithkline Inc,9801000087100,Pediatric vaccine product containing only Hepatitis A + hepatitis B antigens low strength (medicinal product),Hepatitis A + B pediatric,HAHB ped,871803007,Vaccine product containing only Hepatitis A and Hepatitis B virus antigens (medicinal product),Hepatitis A + Hepatitis B,HAHB,J07BC20,combinations,HAHB TWINRIX Junior GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00028267.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60885
02242727,Health_Canada,02242727,,Typherix,7301000087104,TYPHERIX 25 micrograms per 0.5 milliliter liquid for injection GlaxoSmithKline Inc. (real clinical drug),liquid,intramuscular,733020007,Syringe (unit of presentation),,1,salmonella typhi vi capsular polysaccharide vaccine 25 mcg / 0.5 mL liquid for injection,Glaxosmithkline Inc,2171000221104,Vaccine product containing only Salmonella enterica subspecies enterica serovar Typhi capsular polysaccharide unconjugated antigen in parenteral dose form (medicinal product form),Typhoid inactivated unconjugated,Typh-I uncong,961000221100,Vaccine product containing only Salmonella enterica subspecies enterica serovar Typhi antigen (medicinal product),Typhoid inactivated,Typh-I,J07AP03,"typhoid, purified polysaccharide antigen",Typh-I TYPHERIX GSK,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00023826.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66534
02130955,Health_Canada,02130955,,Typhim Vi,7311000087102,TYPHIM Vi 25 micrograms per 0.5 milliliter solution for injection Sanofi Pasteur Limited (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),Single-dose prefilled syringe,1,salmonella typhi ty2 vi capsular polysaccharide 25 mcg / 0.5 mL solution for injection,Sanofi Pasteur Limited,2171000221104,Vaccine product containing only Salmonella enterica subspecies enterica serovar Typhi capsular polysaccharide unconjugated antigen in parenteral dose form (medicinal product form),Typhoid inactivated unconjugated,Typh-I uncong,961000221100,Vaccine product containing only Salmonella enterica subspecies enterica serovar Typhi antigen (medicinal product),Typhoid inactivated,Typh-I,J07AP03,"typhoid, purified polysaccharide antigen",Typh-I TYPHIM Vi SP,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00061819.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20287
02229702,Health_Canada,02229702,66124794,Vaqta,6901000087101,VAQTA 50 units per milliliter suspension for injection Merck Canada Inc. (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),,1,"hepatitis a vaccine, inactivated 50 unit / mL suspension for injection",Merck Canada Inc,19371000087102,Adult vaccine product containing only Hepatitis A virus regular strength antigen (medicinal product),Hepatitis A adult,HA adult,871751006,Vaccine product containing only Hepatitis A virus antigen (medicinal product),Hepatitis A,HA,J07BC02,"hepatitis a, inactivated, whole virus",HA VAQTA Merck,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00019913.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47865
6891000087102,SNOMED-CT,02229702,66124795,Vaqta Pediatric,6891000087102,VAQTA 25 units per 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),,1,"hepatitis a vaccine, inactivated 50 unit / mL suspension for injection",Merck Canada Inc,9811000087103,Pediatric vaccine product containing only Hepatitis A virus low strength antigen (medicinal product),Hepatitis A pediatric,HA ped,871751006,Vaccine product containing only Hepatitis A virus antigen (medicinal product),Hepatitis A,HA,J07BC02,"hepatitis a, inactivated, whole virus",HA VAQTA pediatric Merck,Marketed,Added,2024-11-24,https://pdf.hres.ca/dpd_pm/00019913.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47865
02241047,Health_Canada,02241047,66124796,Varilrix,31541000087105,VARILRIX not less than 1995 plaque forming units per 0.5 milliliter powder and diluent for solution for injection GlaxoSmithKline Inc. (real clinical drug),powder for solution,subcutaneous,733026001,Vial (unit of presentation),,2,varicella-zoster virus vaccine live attenuated (oka-strain) 1995 PFU / 0.5 mL + water 0.5 ml powder for solution for injection,Glaxosmithkline Inc,28441000087100,Vaccine product containing only Human alphaherpesvirus 3 antigen for varicella prevention (medicinal product),Varicella live attenuated,Var-LA,28441000087100,Vaccine product containing only Human alphaherpesvirus 3 antigen for varicella prevention (medicinal product),Varicella,Var,J07BK01,"varicella, live attenuated",Var VARILRIX GSK,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00052674.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64641
02246081,Health_Canada,02246081,66124797,Varivax III,7241000087105,VARIVAX III 1350 plaque forming units powder and diluent for solution for injection Merck Canada Inc. (real clinical drug),powder for solution,subcutaneous OR intramuscular,733026001,Vial (unit of presentation),Single dose vials,1,varicella virus live attenuated (oka/merck strain) 1350 unit / 0.5 mL powder for solution for injection,Merck Canada Inc,28441000087100,Vaccine product containing only Human alphaherpesvirus 3 antigen for varicella prevention (medicinal product),Varicella live attenuated,Var-LA,28441000087100,Vaccine product containing only Human alphaherpesvirus 3 antigen for varicella prevention (medicinal product),Varicella,Var,J07BK01,"varicella, live attenuated",Var VARIVAX III Merck,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00058898.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70216
02442183,Health_Canada,02442183,66124835,Varizig,57891000087108,VariZIG 125 international units per 1.2 milliliter solution for injection KI BioPharma LLC (real clinical drug),solution,intramuscular OR intravenous,733026001,Vial (unit of presentation),Also known as varicella zoster immune globulin human. single use vial,1,varicella zoster immunoglobulin (human) 125 unit / vial solution for injection,Ki Biopharma Llc,784463006,Product containing precisely Varicella-zoster virus antibody 104 unit/1 milliliter conventional release solution for injection (clinical drug),Varicella immunoglobulin 104 units/ml,VarIg-104,62294009,Product containing varicella-zoster immune globulin (medicinal product),Varicella immunoglobulin,Var Ig,J06BB03,varicella/zoster immunoglobulin,VarIg VariZIG KIB,Marketed,Modified,2024-09-19,https://pdf.hres.ca/dpd_pm/00064236.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92654
02538164,Health_Canada,02538164,,Vaxchora,60261000087109,VAXCHORA 400000000 to 2000000000 colony forming units per sachet powder for oral suspension Bavarian Nordic AS (real clinical drug),powder for suspension,oral,733013000,Sachet (unit of presentation),Also contains one 4.5 g buffer component sachet,1,"vibrio cholerae, strain cvd 103-hgr, live 2000000000 unit / 2 g oral powder for suspension",Bavarian Nordic As,1011000221100,Vaccine product containing only live attenuated Vibrio cholerae antigen in oral dose form (medicinal product form),Cholera live attenuated oral,Chol-O-LA,991000221105,Vaccine product containing only Vibrio cholerae antigen (medicinal product),Cholera,Chol,J07AE02,"cholera, live attenuated",Chol-O VAXCHORA BN,Marketed,Added,2024-09-19,https://pdf.hres.ca/dpd_pm/00074201.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102690
02223929,Health_Canada,02223929,66124798,Vaxigrip,7561000087109,Vaxigrip 15 micrograms per 0.5 milliliter suspension for injection Sanofi Pasteur SA (real clinical drug),suspension,intramuscular,733026001,Vial (unit of presentation),5ml multidose vial,3,haemagglutinin-strain a (h1n1) 15 mcg / 0.5 mL + haemagglutinin-strain a (h3n2) 15 mcg / 0.5 mL + haemagglutinin-strain b 15 mcg / 0.5 mL suspension for injection,Sanofi Pasteur Limited,28191000087104,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B unadjuvanted standard dose,Inf H1N1+H3N2+B unadj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf VAXIGRIP SP,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00025395.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=37348
02522403,Health_Canada,02522403,,Vaxneuvance,37891000087107,VAXNEUVANCE 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug),suspension,intramuscular,733020007,Syringe (unit of presentation),Prefilled syringe - single dose,16,corynebacterium diphtheriae crm-197 protein 30 mcg / 0.5 mL + pneumococcal polysaccharide serotype 1 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 14 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 18c 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 19a 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 19f 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 22f 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 23f 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 3 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 33f 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 4 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 5 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 6a 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 6b 4 mcg / 0.5 mL + pneumococcal polysaccharide serotype 7f 2 mcg / 0.5 mL + pneumococcal polysaccharide serotype 9v 2 mcg / 0.5 mL suspension for injection,Merck Canada Inc,1252708008,"Vaccine product containing only Streptococcus pneumoniae Danish serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F capsular polysaccharide conjugated antigens (medicinal product)",Pneumococal conjugated 15 valent,Pneu-C-15,981000221107,Vaccine product containing only Streptococcus pneumoniae antigen (medicinal product),Pneumococcal,Pneu,J07AL02,"pneumococcus, purified polysacc.antigen conjugated",Pneu-C-15 VAXNEUVANCE Merck,Marketed,Added,2022-12-11,https://pdf.hres.ca/dpd_pm/00063580.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101153
02510847,Health_Canada,02510847,,Vaxzevria,28761000087108,VAXZEVRIA non-replicant vector 0.5 milliliter solution for injection AstraZeneca Canada Inc. (real clinical drug),solution,intramuscular,733026001,Vial (unit of presentation),Vial contains 10 doses of 0.5ml,1,chadox1-s [recombinant] 50000000000 vaginal pessary / 0.5 mL solution for injection,Astrazeneca Canada Inc,29061000087103,Vaccine product containing only recombinant non-replicating viral vector encoding severe acute respiratory syndrome coronavirus 2 spike protein (medicinal product),COVID-19 non-replicating vector,COVID-19 NRV,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN02,"covid-19, viral vector, non-replicating",COVID-19 VAXZEVRIA AZC,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00065692.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100004
45391000087107,SNOMED-CT,,,VidPrevtyn Beta,45391000087107,VidPrevtyn Beta recombinant spike protein 5 micrograms per 0.5 milliliter emulsion for injection Sanofi Pasteur Ltd. (real clinical drug),,,,,,,,Sanofi Pasteur Ltd.,1162643001,Vaccine product containing only Severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN04,covid-19 protein subunit,COVID-19 VivPrevtyn,International,Added,2023-03-21,https://www.ema.europa.eu/en/documents/product-information/vidprevtyn-beta-epar-product-information_en.pdf,
02248361,Health_Canada,02248361,,Vivaxim,7331000087107,ViVAXIM 160 antigen units and 25 micrograms suspension for injection Sanofi Pasteur Limited (real clinical drug),solution AND suspension,intramuscular,733020007,Syringe (unit of presentation),,2,"hepatitis a vaccine, inactivated 160 unit / 0.5 mL + salmonella typhi vi capsular polysaccharide vaccine 25 mcg / 0.5 mL solution or suspension for injection",Sanofi Pasteur Limited,871804001,Vaccine product containing only Hepatitis A virus and Salmonella enterica subspecies enterica serovar Typhi antigens (medicinal product),Hepatitis A + Typhoid Inactivated,HA-Typh-I,871804001,Vaccine product containing only Hepatitis A virus and Salmonella enterica subspecies enterica serovar Typhi antigens (medicinal product),Hepatitis A + Typhoid,HA-Typh,J07CA10,typhoid-hepatitis a,HA-Typh-I ViVAXIM SP,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00032177.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72706
00885975,Health_Canada,00885975,,Vivotif,57861000087100,Vivotif 10 billion units enteric coated capsule Bavarian Nordic AS (real clinical drug),capsule (enteric-coated),oral,732937005,Capsule (unit of presentation),,1,salmonella typhi ty21a live attenuated 10000000000 CFU oral gastro-resistant capsule,Bavarian Nordic As,971000221109,Vaccine product containing only live attenuated Salmonella enterica subspecies enterica serovar Typhi antigen in oral dose form (medicinal product form),Typhoid live attenuated oral,Typh-O LA,971000221109,Vaccine product containing only live attenuated Salmonella enterica subspecies enterica serovar Typhi antigen in oral dose form (medicinal product form),Typhoid oral,Typh-O,J07AP01,"typhoid, oral, live attenuated",Typh-O Vivotif BN,Marketed,Modified,2024-06-03,https://pdf.hres.ca/dpd_pm/00073936.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13630
19291000087108,SNOMED-CT,,,Xanaflu,19291000087108,"Xanaflu 15 micrograms per 0.5 milliliter suspension for injection Drug Safety, Abbott Laboratories, Limited (real clinical drug)",,,,,,,,"Abbott Laboratories, Limited",28191000087104,Unadjuvanted vaccine product containing only Influenza A virus subtypes H1N1 and H3N2 and Influenza B virus standard dose each non-live antigen in parenteral dose form (medicinal product form),Influenza H1N1+H3N2+B unadjuvanted standard dose,Inf H1N1+H3N2+B unadj,1181000221105,Vaccine product containing only Influenza virus antigen (medicinal product),Influenza,Inf,J07BB02,"influenza, inactivated, split virus or surface antigen",Inf Xanaflu API,International,Added,2022-03-31,http://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Immunization/Vaccine%20Info/Archived_Supplemental_Seasonal_InfluenzaVaccineQandA-Jan2014.pdf,
00428833,Health_Canada,00428833,,Yf-Vax,7221000087101,YF-VAX 109648 plaque forming units per 0.5 milliliter powder and diluent for suspension for injection Sanofi Pasteur Limited (real clinical drug),powder for solution,subcutaneous,733026001,Vial (unit of presentation),,1,yellow fever vaccine 109648 PFU / 0.5 mL powder for solution for injection,Sanofi Pasteur Limited,1121000221106,Vaccine product containing only live attenuated Yellow fever virus antigen (medicinal product),Yellow Fever live attenuated,YF-LA,871717007,Vaccine product containing only Yellow fever virus antigen (medicinal product),Yellow fever,YF,J07BL01,"yellow fever, live attenuated",YF-VAX SP,Marketed,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00050691.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2964
33471000087102,SNOMED-CT,,,Zifivax,33471000087102,ZIFIVAX COVID-19 recombinant spike protein vaccine (real medicinal product),,,,,,,,Anhui Zhifei Longcom,1162643001,Vaccine product containing only Severe acute respiratory syndrome coronavirus 2 recombinant spike protein antigen (medicinal product),COVID-19 recombinant spike protein,COVID-19 RSP,28531000087107,Vaccine product against Severe acute respiratory syndrome coronavirus 2 (medicinal product),SARS-CoV-2 vaccine,COVID-19 vac,J07BN04,covid-19 protein subunit,COVID-19 ZIFIVAX,International,Added,2022-03-31,https://covid19.trackvaccines.org/vaccines/27/,
02315939,Health_Canada,02315939,,Zostavax,7411000087108,ZOSTAVAX 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug),powder for suspension,subcutaneous,733026001,Vial (unit of presentation),,1,varicella-zoster virus vaccine live attenuated (oka/merck strain) 19400 PFU / 0.65 mL powder for suspension for injection,Merck Canada Inc,56341000087108,Vaccine product containing only live attenuated Human alphaherpesvirus 3 antigen for herpes zoster prevention (medicinal product),Zoster live attenuated,LZV,28451000087102,Vaccine product containing only Human alphaherpesvirus 3 antigen for herpes zoster prevention (medicinal product),Zoster,Zos,J07BK02,"zoster, live attenuated",LZV ZOSTAVAX MC,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00026587.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80146
02375516,Health_Canada,02375516,,Zostavax III,19321000087101,ZOSTAVAX II 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug),powder for suspension,subcutaneous,733026001,Vial (unit of presentation),0.65ml single-dose vial. refrigerator stable.,1,varicella-zoster virus vaccine live attenuated (oka/merck strain) 19400 PFU / 0.65 mL powder for suspension for injection,Merck Canada Inc,56341000087108,Vaccine product containing only live attenuated Human alphaherpesvirus 3 antigen for herpes zoster prevention (medicinal product),Zoster live attenuated,LZV,28451000087102,Vaccine product containing only Human alphaherpesvirus 3 antigen for herpes zoster prevention (medicinal product),Zoster,Zos,J07BK02,"zoster, live attenuated",LZV ZOSTAVAX II MC,Cancelled post market,Added,2022-03-31,https://pdf.hres.ca/dpd_pm/00048400.PDF,https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86093
